WO2003000685A1 - 5-membered heterocycle derivatives - Google Patents

Abstract

Compounds represented by the general formula (|) or salts thereof, useful as preventive and therapeutic drugs for diabetes and so on: (|) wherein R1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; X and Y are each independently a free valency or the like; Q is a bivalent hydrocarbon residue having 1 to 20 carbon atoms; A is an aromatic ring which may further bear one to three substituents; n is an integer of 1 to 8; B is a nitrogenous 5-membered heterocycle which may further bear one to three substituents; W is a bivalent hydrocarbon residue having 1 to 20 carbon atoms; V is a free valency or the like; and R2 is an optionally substituted heterocyclic group or the like.

Description

Technical field

 The present invention relates to a novel 5-membered heterocyclic derivative having an excellent blood glucose lowering action and blood lipid lowering action, and being useful as an agent for preventing and treating diabetes, hyperlipidemia, impaired glucose tolerance, and the like.

 Light

Background art

 As the 5-membered heterocyclic derivative, compounds described in the following documents are known.

 book

(1) WO 00/64876 includes, as a PP AR ligand receptor binding agent,

 [Where, is

Independently, aryl, etc .; A is —O—, etc .; B is one O—, etc .; D is one O—, etc .; E is a bond or an ethylene group; a, b, c and e is 0-4; d is 0-5; f is 0-6; R ₃ , R ₅ , R ₇ , R ₉ and are independently hydrogen or the like; R ₂ , R ₄ , R ₆ , the Q is _{0- 3;; R 8, R} 10 and R ₁₂ are independently - - (CH) _q and X X hydrogen etc.; Z is R ₂₁ 0 ₂ C- and the like; R ₂₁ is hydrogen, etc. Is shown].

(2) WO 01 / 179.94 states that compounds that bind to P PAR — <<, PPAR— and PPAR-1δ to act

 [Wherein X represents 0, S or NH, R represents methyl, ethyl, n-propyl, i-propyl, cyclopropyl, n-butyl, phenyl or 1 C {0C}], and a compound represented by the formula:

Wherein, X is C or N, R is methyl, Echiru, n- propyl, i _ propyl, - C 0C¾ or a C0 indicates ₂ CH _3] a compound represented by is described. (3) W001 / 38325 includes a retinoid-related receptor function modulator

R -X- (CH ₂ ) _m -Y -ir (I)

[Wherein, R ¹ represents an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; X represents a bond, 0, S, —CO—, —CS—, one CR ⁴ (0R ⁵ ) —or—NR ⁶ — (R ⁴ and R ⁶ represent a hydrogen atom or an optionally substituted hydrocarbon group, and R ⁵ represents a hydrogen atom or a hydroxyl-protecting group); the; Y is 0, S, one _{SO -, _ S0 2 _,} -NR 7 -, _C0NR 7 _ or a NR ⁷ C0_ the (R ⁷ is a hydrogen atom or an optionally substituted hydrocarbon group); Ring A may further have 1 to 3 substituents An aromatic ring; n is 1-8; ring B is a nitrogen-containing 5-membered heterocyclic ring which may be further substituted with an alkyl group; X ¹ is a bond, 0, S, one SO—, one S0 ₂ — 1—S0 ₂ —or—NR ¹⁶ — (R ¹⁶ represents a hydrogen atom or an optionally substituted hydrocarbon group); 2 is a hydrogen atom, an optionally substituted hydrocarbon group or substituted W may be a bond or ₂ ; R ³ represents -OR ⁸ (R ⁸ represents a hydrogen atom or an optionally substituted hydrocarbon group) or -NR ⁹ R ^1G (R ⁹ and R ¹¹¹ represent The same or different, represents a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group or an optionally substituted acyl group, or R ⁹ and R ^1Q are Bond to form a ring). "

Peroxisome proliferator-activated receptor gamma (PPARr) is a member of the superfamily of nuclear hormone receptors represented by the steroid hormone receptor and thyroid hormone receptor. Its expression is induced and plays an important role in adipocyte differentiation as a master regulator. PPARr forms a dimer with the retinoid X receptor (RX) by binding to a ligand, and binds to the responsive site of the target gene in the nucleus to directly control (activate) the transcription efficiency. I have. Recently, a metabolite of prostaglandin D ₂ 15-Dokishi - delta ¹² · ¹⁴ prostaglandin J ₂ are likely to be endogenous ligands for P PAR § suggested, furthermore, is represented cash to thiazolidinedione derivative It has been found that a kind of insulin sensitivity enhancer has the ligand activity of PPARa, and its strength is paralleled by its hypoglycemic action or adipocyte differentiation promoting action [Cell, 83, 803 (1995) Year); The Journal of Biological Chemistry, 270, 12953 (1995): Journal of Medicinal Chemistry, 39 655 pages (1996)]. Furthermore, recently, 1) the expression of PPART in cultured cells derived from human liposarcoma and the cessation of its proliferation by the addition of PPAR ligands [Procedures of the National Academy] Proceedings of the United States The National Academy of Sciences of The United States of America), vol. 94, p. 237, (1997)], .2) Non-steroidal anti-inflammatory drugs represented by indomethacin and phenobrophene have PP AR ligand activity [The Journal of Biological Chemistry, vol. 272, p. 3406 (1997)], 3) High expression of PPARa in activated macrophages Inhibition of transcription of genes involved in inflammation by the addition of ligand [Nature, 391, 79 (1998)], 4) PPARa ligand activates inflammatory site by monocytes Inhibiting the production of in (TNFo !, IL-1) 3, IL-6) [Nature, 391, 82 (1998)], 5) Adipocytes in PPAR heterozygous mice Hypertrophy, fat accumulation, and insulin resistance And [Molecular Cell, Volume 4, pp. 597 (1999)], 6) PPART ligand inhibits the differentiation of 10T1 / 2 cells into adipocytes by PPARagogist [Proceedings of the National Academy of Sciences of The United States of America] [Procedings of the National Academy of Sciences of the United States of America] > 96, 610, 2 (1999)], 7) PPARr ligand inhibits the differentiation of 3T3-L1 cells into adipocytes by PPARr agonist [Molecular Endocrinology], 14 , 1425, (2000)].

 The development of new compounds that are useful as preventive and therapeutic agents for diabetes, hyperlipidemia, impaired glucose tolerance, etc., and have excellent properties as pharmaceuticals, such as having few side effects, is expected. Disclosure of the invention

 The present invention

1) General formula Two

R -XQY- A (CH ₂ ) WVR (I)

[Wherein, R ¹ is an optionally substituted hydrocarbon group or an optionally substituted

X and Y are the same or different bond, an oxygen atom, a sulfur atom, One CO-, One CS-, One SO- one S_〇 _{^{2 -, -CR 3 (OR 4}} ) one one NR ⁵ - one CO NR ⁶ — or one NR ⁶ C 〇 (R ³ is a hydrogen atom or a hydrocarbon group which may be substituted, R ⁴ is a hydrogen atom or a hydroxyl-protecting group, R ⁵ is a hydrogen atom, And R ⁶ represents a hydrogen atom or an optionally substituted hydrocarbon group N).

Q represents a divalent hydrocarbon residue having 1 to 20 carbon atoms;

Ring A is an aromatic ring which may further have 1 to 3 substituents; n is an integer of 1 to 8;

Ring B is a nitrogen-containing 5-membered heterocyclic ring which may further have 1 to 3 substituents;

 W represents a divalent hydrocarbon residue having 1 to 20 carbon atoms;

V represents a bond, an oxygen atom, a sulfur atom, —SO—, one SO ₂ —, — NR ⁷ — or one NR ⁷ CO— (R ⁷ represents a hydrogen atom or an optionally substituted hydrocarbon group )

R ² is —PO (OR ⁸ ) (OR ⁹ ) (R ⁸ and R ⁹ are the same or different and each represent a hydrogen atom or an optionally substituted hydrocarbon group, and R ⁸ and R ⁹ are May form a ring which may be substituted), -COR ¹⁰ (R ^1G represents a hydrogen atom or a hydrocarbon group which may be substituted), a hydrocarbon group which may be substituted or substituted A heterocyclic group which may be substituted.

However, Ring B has the formula: - Wa- (C = 0) - R a (Wa is a divalent hydrocarbon residue bond or a C 1 to 20, R ^a one 0R ^b (R ^b are hydrogen An atom or an optionally substituted hydrocarbon group) or NR (and ^Rd are the same or different and are a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, Or an optionally substituted acyl group, and R ^e and R ^d are a bond Which may form a ring).

When V is a bond, R ² is — (C = 0) —R ^e (R ^e is one ^Rf (R ^f is a hydrogen atom or an optionally substituted hydrocarbon group) or — NR ^g R ^h (R ^g and R ^h are the same or different and represent a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, or an optionally substituted acyl group. And R ^g and R ^h may be bonded to each other to form a ring).) Is not a hydrocarbon group substituted with the substituent represented by 2) X is a bond, an oxygen atom, a sulfur atom, —CO—, —CS—, —CR ³ (OR ⁴ ) — or —NR ⁵ — (R ³ is a hydrogen atom Or an optionally substituted hydrocarbon group, R ⁴ represents a hydrogen atom or a protecting group for a hydroxyl group, and R ⁵ represents a hydrogen atom, an optionally substituted hydrocarbon group or a protecting group for an amino group); And

Y is a bond, an oxygen atom, a sulfur atom, - SO -, one S0 ₂ -, -NR ⁶ -, one C ONR ⁶ - or - NR ⁶ CO- (R ⁶ is not good be hydrogen atom or a substituent The compound according to the above 1), which represents a hydrocarbon group);

3) The compound according to the above 1), wherein R ¹ is an optionally substituted heterocyclic group;

4) The compound according to 1), wherein X is a bond;

 5) The compound according to the above 1), wherein Y is an oxygen atom;

 6) The compound according to the above 1), wherein the substituent which ring B may further have is a hydrocarbon group;

7) The compound according to 6), wherein the hydrocarbon group is an alkyl group having 1 to 10 carbon atoms, an aralkyl group having 7 to 13 carbon atoms, or an aryl group having 6 to 14 carbon atoms;

 8) The compound according to 1), wherein V is a bond;

9) R ² gar ^{PO (OR 8) (OR 9} ) (R 8 and R ⁹ are the same or different dates Te hydrogen atom or an optionally substituted hydrocarbon group, and R ⁸ and R

⁹ may be bonded to form an optionally substituted ring), —COR ¹⁰ (R ^1Q represents a hydrogen atom or an optionally substituted hydrocarbon group) or may be substituted The compound according to the above 1), which is a good heterocyclic group;

10) a prodrug of the compound of 1) or a salt thereof; 11) a pharmaceutical composition comprising the compound according to 1) or a salt thereof or a prodrug thereof;

 12) The pharmaceutical composition according to the above 11), which is an agent for preventing or treating diabetes.

 13) The pharmaceutical composition according to the above 11), which is a preventive or therapeutic agent for hyperlipidemia;

 14) Prevention of impaired glucose tolerance * The pharmaceutical composition according to 11) above, which is a therapeutic agent.

 15) The pharmaceutical composition according to the above 11), which is an agent for preventing and treating obesity;

 16) a retinoid-related receptor function modulator comprising the compound according to 1) or a salt thereof or a prodrug thereof;

 17) The agent according to the above 16), which is a peroxisome proliferator-activated receptor ligand;

 18) The agent according to the above 16), which is a retinoid X receptor ligand;

 19) An insulin sensitizer comprising the compound according to 1) or a salt thereof or a prodrug thereof;

 20) A method for treating diabetes in a mammal, comprising administering the compound according to 1) or a salt thereof or a prodrug thereof to a mammal; 21) the compound according to 1) or a salt thereof or a prodrug thereof. 22. A method for treating hyperlipidemia in a mammal, which comprises administering the drug to the mammal; 22) administering the compound according to 1) or a salt thereof or a prodrug thereof to the mammal. A method for treating obesity in the mammal; 23) use of the compound or salt thereof or a prodrug thereof according to 1) for the manufacture of a prophylactic or therapeutic agent for diabetes;

 24) Use of the compound according to 1) or a salt thereof or a prodrug thereof for the manufacture of a prophylactic or therapeutic agent for hyperlipidemia;

25) Use of a compound or a salt thereof or a prodrug thereof according to the above 1) for the manufacture of a prophylactic or therapeutic agent for obesity. In the general formula (I), examples of the hydrocarbon group in the “optionally substituted hydrocarbon group” represented by R ¹ include an aliphatic hydrocarbon group, an alicyclic hydrocarbon group, and an alicyclic monoaliphatic. Aromatic hydrocarbon groups, araliphatic hydrocarbon groups, and aromatic hydrocarbon groups. The number of carbon atoms in these hydrocarbon groups is preferably 1 to 14.

 As the aliphatic hydrocarbon group, an aliphatic hydrocarbon group having 1 to 8 carbon atoms is preferable. Examples of the aliphatic hydrocarbon group include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec.-butyl, t.-butyl, pentyl, isopentyl, neopentyl, hexyl, isohexyl, heptyl, and octyl. Saturated aliphatic hydrocarbon group having 1 to 8 carbon atoms (eg, alkyl group); for example, ethenyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2- Methyl-1-propenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 3-methyl-1-butenyl, 1-hexenyl, 3-hexenyl, 2,4-hexagenyl, 5 —Hexenyl, 1 to 1 • penyl, 1-octenyl, ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-hexynyl, 3-hexynyl, 2,4-hexazinyl, 5-hexynyl, 1-heptinyl, 1-octynyl, etc. (E.g., an alkenyl group having 2 to 8 carbon atoms, an alkadienyl group having 4 to 8 carbon atoms, an alkynyl group having 2 to 8 carbon atoms, an alkadinyl group having 4 to 8 carbon atoms, etc.) No.

 As the alicyclic hydrocarbon group, an alicyclic hydrocarbon group having 3 to 7 carbon atoms is preferable. Examples of the alicyclic hydrocarbon group include a saturated alicyclic hydrocarbon group having 3 to 7 carbon atoms such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl (eg, cycloalkyl group, etc.); For example, 1-cyclopentenyl, 2-cyclopentenyl, 3-cyclopentenyl, 1-cyclohexenyl, 2-cyclohexenyl, 3-cyclohexenyl, 1-cycloheptenyl, 2-cycloheptenyl, 3-cycloheptenyl, And unsaturated alicyclic hydrocarbon groups having 5 to 7 carbon atoms such as 2,4-cycloheptagenyl (eg, cycloalkenyl group, cycloalkadienyl group, etc.).

Examples of the alicyclic monoaliphatic hydrocarbon group include those in which the alicyclic hydrocarbon group is bonded to an aliphatic hydrocarbon group (eg, a cycloalkyl monoalkyl group, a cycloalkenyl alkyl group, and the like). Above all, alicyclic monoaliphatics having 4 to 9 carbon atoms Hydrocarbon groups are preferred. Examples of the alicyclic monoaliphatic hydrocarbon group include cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclopentylmethyl, 2-cyclopentenylmethyl, 3-cyclopentenylmethyl, cyclohexylmethyl, and 2-cyclopentylmethyl. Examples include cyclohexenylmethyl, 3-cyclohexenylmethyl, cyclohexylethyl, cyclohexylpropyl, cycloheptylmethyl, and cycloheptylethyl.

 As the araliphatic hydrocarbon group, an araliphatic hydrocarbon group having 7 to 13 carbon atoms (eg, an aralkyl group having 7 to 13 carbon atoms, an aralkyl alkenyl group having 8 to 13 carbon atoms) is preferable. Examples of the araliphatic hydrocarbon group include phenylalkyl having 7 to 9 carbon atoms such as benzyl, phenyl, 1-phenylethyl, 1-phenylpropyl, 2-phenylpropyl, and 3-phenylpropyl; Naphthylalkyl having 11 to 13 carbon atoms such as methyl, α-naphthylethyl, / 3-naphthylmethyl, i3-naphthylethyl; phenylalkenyl having 8 to 10 carbon atoms such as styryl; 2 — (2-naphthylvinyl And naphthylalkenyl having 12 to 13 carbon atoms.

 As the aromatic hydrocarbon group, an aromatic hydrocarbon group having 6 to 14 carbon atoms (eg, an aryl group) is preferable. Examples of the aromatic hydrocarbon group include phenyl, naphthyl, anthryl, phenanthryl, acenaphthylenyl, biphenylyl and the like, with phenyl, 1-naphthyl and 2-naphthyl being preferred.

 Among the hydrocarbon groups described above, cyclic hydrocarbon groups such as alicyclic hydrocarbon groups and aromatic hydrocarbon groups are preferable. The hydrocarbon group is more preferably an aromatic hydrocarbon group having 6 to 14 carbon atoms, particularly preferably fuel, naphthyl and the like.

In the general formula (I), the heterocyclic group in the “optionally substituted heterocyclic group” represented by R ¹ includes, for example, an oxygen atom, a sulfur atom and a nitrogen atom other than a carbon atom as a ring-constituting atom. And a 5- to 7-membered monocyclic heterocyclic group or fused heterocyclic group containing 1 to 4 heteroatoms selected from The fused heterocyclic group includes, for example, a 5- to 7-membered monocyclic heterocyclic group and one or two nitrogen atoms. And a group in which a 6-membered ring containing a benzene ring or a 5-membered ring containing one sulfur atom is condensed.

 Specific examples of the heterocyclic group include, for example, furyl (2-furyl, 3-furyl), phenyl (2-phenyl, 3-phenyl), pyrrolyl (1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl), imidazolyl (1 1-imidazolyl, 2r-midazolyl, 4-imidazolyl, 5-imidazolyl), pyrazolyl (1-pyrazolyl, 3-pyrazolyl, 4-pyrazolyl), isooxazolyl (3-isoxoxazolyl, 4-isoxazolyl, 5- ^ Γoxoxazolyl) , Isothiazolyl (3-isothiazolyl, 4-isothiazolyl, 5-isothiazolyl), thiazolyl (2-thiazolyl, 4-dithiazolyl, 5-diazolyl), oxazozolyl (2-diluted xazolyl, 4-diluted xazolyl, 5-digested xazolyl) , Okisaziazolyl (1, 2, 4 _ Okisaziazoru 3-^ T, 1, 2, 4 Saziazol-5-yl, 1,3,4-oxaziazol-2-yl), thiadiazolyl (1,3,4-thiadiazol-2-yl), triazolyl (1,2,4-triazolyl-1) _______________, 1, 2, 4_triazo-l- 3-yl, 1, 2, 3-triazo-l-l_ 1_yl, 1, 2, 3-triazole-

2-yl, 1,2,3-triazolyl 4 f), tetrazolyl (tetrazoyl 11-yl, tetrazole 5-yl), pyridyl (2-pyridyl,

3-pyridyl, 4-pyridyl), pyrimidinyl (2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 6-pyrimidinyl), pyridazinyl (3-pyridazinyl, 4-pyridazinyl), virazinyl (2-pyragel), quinolyl ( 2-quinolyl, 3-quinolyl, 4-quinolyl), quinazolyl (2-quinazolyl, 4-quinazolyl), quinoxalyl (2-quinoxalyl), benzoxazolyl (2-benzozoxazolyl), benzothiazolyl (2-benzothiazolyl) , Benzimidazolyl (benzimidazol-l-yl, benzimidazole-l-yl), indolyl (Indian l-lll-yl, India l-l 3-^^), indazolyl (1H-indazole-3-yl) ), Pyrrolopyrazinyl (1H-pyrro [2,3-b] pyrazin-1-yl), B) Pyridinyl (1H-pyro [2,3-b] pyridine-6-yl), imidazo Pyridinyl (1H-imidazo [4,5-b] pyridine-12-yl, 1H-imidazo [4,5-c] pyridine-12-yl), imidazopyragel (1H-imidazo [4 , 5-b] pyrazine-2-yl), benzotriazolyl (benzotriazoyl-11-yl) and other aromatic heterocyclic groups; and pyrrolidinyl (1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl) , Imidazolidinyl (2-imidazolidinyl, 4-imidazolidinyl), pyrazolidinyl (2-pyrazolidinyl, 3-virazolidinyl, 4-pyrazolidinyl), thiazolidinyl (thiazolidine-3-yl), oxazolidinyl (oxazolidine) Oxoimidazolidinyl (2-oxoimidazolidinyl 1-yl), dioxoimidazolidinyl (2,4-dioxoimidazolidinyl 3-) ), Dioxoxazolidinyl (2,4-dioxoxazolidine 13-yl), dioxothiazolidinyl (2,4-dioxothiazolidine 13-yl) ), Piperidino, morpholino, thiomorpholino, piperazinyl (1-piperazinyl), hexamethyleneiminyl (hexamethyleneimine-1-yl), oxophthalagel (1-oxo-phthalazine-1 2-) Non-aromatic heterocyclic groups such as benzodiazinyl and benzodithiazinyl benzothiazinyl (2-oxo-2,3-dihydro-4H-1, 4-benzothiazin-14-yl). The heterocyclic group is preferably an aromatic heterocyclic group. In the general formula (I), the hydrocarbon group and the heterocyclic group represented by R ¹ may each have 1 to 5, preferably 1 to 3 substituents at substitutional positions. Examples of such a substituent include “halogen atom”, “nitro group”, “optionally substituted aliphatic hydrocarbon group”, “optionally substituted alicyclic hydrocarbon group”, 'Optionally substituted aromatic hydrocarbon group', 'optionally substituted aromatic heterocyclic group', 'optionally substituted non-aromatic heterocyclic group', 'acyl group', ' An optionally substituted amino group, an optionally substituted hydroxy group, an optionally substituted thiol group, an optionally esterified or amidated propyloxyl group And the like.

"Halogen atom" includes fluorine, chlorine, bromine and iodine, Of these, fluorine and chlorine are preferred.

 Examples of the aliphatic hydrocarbon group in the “optionally substituted aliphatic hydrocarbon group” include a linear or branched aliphatic hydrocarbon group having 1 to 15 carbon atoms, for example, an alkyl group and an alkenyl group. And alkynyl groups.

 Preferable examples of the alkyl group include an alkyl group having 1 to 10 carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec.-butyl, t.-butyl, pentyl, isopentyl, neopentyl, 1 Examples include monoethylpropyl, hexyl, isohexyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, 2-ethylbutyl, heptyl, octyl, nonyl, and decyl.

 Preferred examples of the alkenyl group include alkenyl groups having 2 to 10 carbon atoms, for example, ethenyl, 1-propenyl, 2-propenyl, 2-methyl-1-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 3-methyl-2-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 4-methyl-3-pentenyl, 1-hexenyl, 3-hexenyl, 5- Hexenyl, 11-heptur, 1-octenyl and the like.

 Preferable examples of the alkynyl group include alkynyl groups having 2 to 10 carbon atoms, such as ethynyl, 1-propyl, 2-propynyl, 1-butynyl, 2-butenyl, 3-butynyl, 1-pentynyl, 2-pentynyl, and 31-alkynyl. Examples include pentynyl, 4-pentynyl, 1-hexynyl, 21-hexynyl, 31-hexynyl, 4-hexynyl, 5-hexynyl, 1-1 heptynyl, and 11-year-old cutinyl.

Examples of the substituent in the “optionally substituted aliphatic hydrocarbon group” include a cycloalkyl group having 3 to 10 carbon atoms, an aryl group having 6 to 14 carbon atoms (eg, phenyl, naphthyl, etc.), Aromatic heterocyclic groups (eg, chenyl, furyl, pyridyl, oxazolyl, thiazolyl, etc.), non-aromatic heterocyclic groups (eg, tetrahydrofuryl, morpholino, thiomorpholino, piperidino, pyrrolidinyl, piperazinyl, piperazinyl, etc.), amino groups, Amino group, amidino group, mono- or di-substituted with an alkyl group having 1 to 4 carbon atoms or an acyl group having 2 to 8 carbon atoms (eg, alkanoyl group, etc.), an acyl group having 2 to 8 carbon atoms (eg, alkanoyl Group), A carbamoyl group, a mono- or di-substituted alkyl group having 1 to 4 carbon atoms, a rubamoyl group, a sulfamoyl group, a mono- or di-substituted alkyl group having 1 to 4 carbon atoms, a sulfamoyl group, An alkoxycarbonyl group having 2 to 8 carbon atoms, a hydroxy group, an alkoxy group having 1 to 6 carbon atoms which may be substituted with 1 to 3 halogen atoms (eg, fluorine, chlorine, bromine, iodine, etc.); An alkenyloxy group having 2 to 5 carbon atoms, a cycloalkyloxy group having 3 to 7 carbon atoms, carbon atom which may be substituted by 1 to 3 halogen atoms (eg, fluorine, chlorine, bromine, iodine, etc.) Aralkyloxy group having 7 to 9 carbon atoms, aryloxy group having 6 to 14 carbon atoms (eg, phenyloxy, naphthyloxy, etc.), thiol group, 1 to 3 halogen atoms (eg, fluorine, salt , Bromine, iodine, etc.) alkylthio group having 1 to 6 carbon atoms, aralkylthio group having 7 to 9 carbon atoms, arylthio group having 6 to 14 carbon atoms (e.g., phenylthio, Naphthylthio), sulfo group, cyano group, azide group, nitro group, nitroso group, halogen atom (eg, fluorine, chlorine, bromine, iodine) and the like. The number of substituents is, for example, 1 to 3.

 Examples of the alicyclic hydrocarbon group in the “optionally substituted alicyclic hydrocarbon group” include a saturated or unsaturated alicyclic hydrocarbon group having 3 to 12 carbon atoms, for example, a cycloalkyl group, Examples thereof include a cycloalkenyl group and a cycloalkadienyl group.

 Preferable examples of the cycloalkyl group include a cycloalkyl group having 3 to 10 carbon atoms such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo [2.2.1] heptyl, bicyclo [2.2.2] octyl, bicyclo [3.2.1] octyl, bicyclo [3.2.2] nonyl, bicyclo [3.3.1] noel, bicyclo [4.2.1] nonyl, Picicyclo [4.3.1] decyl.

Preferable examples of the cycloalkenyl group include a cycloalkenyl group having 3 to 10 carbon atoms, for example, 2-cyclopentene-11-yl, 3-cyclopentene-11-yl, 2-cyclohexene-11-yl, 3-Hexone 1 f. Preferable examples of the cycloalkadienyl group include a cycloalkadienyl group having 4 to 10 carbon atoms, for example, 2,4-cyclopentadiene-11-yl, 2,4-cyclohexadiene-1_yl, 2, 5-cyclohexadiene 1-yl and the like.

 Preferable examples of the aromatic hydrocarbon group in the “optionally substituted aromatic hydrocarbon group” include an aromatic hydrocarbon group having 6 to 14 carbon atoms (eg, an aryl group, etc.), for example, Examples thereof include phenyl, naphthyl, anthryl, phenanthryl, acenaphthyl, biphenylyl and the like, with phenyl, 1.1-naphthyl, 2-naphthyl and the like being preferred.

 Examples of the aromatic heterocyclic group in the “optionally substituted aromatic heterocyclic group” include, for example, 1 to 5 heteroatoms selected from oxygen, sulfur, and nitrogen atoms in addition to carbon atoms as ring constituent atoms. And a monocyclic, bicyclic or tricyclic aromatic heterocyclic group.

 Preferred examples of the monocyclic aromatic heterocyclic group include furyl, phenyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxaziazolyl (1,2,3-oxaziazolyl, 1,2,41-41). Oxadiazolyl, 1,3,4 monoxadiazolyl), furzanil, thiadiazolyl (1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,3,4_thiadiazolyl), tritriazolyl (1,2,3-triazolyl) Ryl, 1,2,4-triazolyl), tetrazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl and the like.

Preferable examples of the bicyclic or tricyclic aromatic heterocyclic group include benzofuranyl, isobenzofuranyl, benzo [b] chenyl, indolyl, isoindolyl, 1H-indazolyl, benzimidazolyl, benzozo Xazolyl, benzothiazolyl, 1H-benzotriazolyl, quinolyl, isoquinolyl, cinnolyl, quinazolyl, quinoxalinyl, phthalagel, naphthyridiel, purinyl, pteridinyl, carbazolyl, 《—carborilyl, β-propanolyl, r-1 Luponiryl, acridinyl, phenoxazinyl, phenothiazinyl, phenazinyl, phenoxathiinyl, thianthrenyl, indolizini [1,2—b] pyridazinyl, pyrazo [1,5—a] pyridyl, imidazo [1,2—a] pyridyl, imidazo [1,5—a] pyridyl, imidazo [1,2 _ b] pyridazinyl, imidazo [1,2-a] pyrimidinyl, 1,2,4-triazolo [4,3-a] pyridyl, 1,2,4-triazolo [4,3-b] pyridazinyl and the like .

 Examples of the non-aromatic heterocyclic group in the “optionally substituted non-aromatic heterocyclic group” include, for example, a heteroatom selected from an oxygen atom, a sulfur atom and a nitrogen atom in addition to a carbon atom as a ring-constituting atom. And 3 to 3 non-aromatic heterocyclic groups having 2 to 10 carbon atoms. Preferable examples of the non-aromatic heterocyclic group include oxilanyl, azetidinyl, oxetanyl, cesinyl, pyrrolidinyl, tetrahydrofuryl, tetrahydroviranyl, morpholinel, thiomorpholinyl, piperazinyl, pyrrolidinyl, piperidino, morpholinomorpholino And the like.

The aforementioned “optionally substituted alicyclic hydrocarbon group”, “optionally substituted aromatic hydrocarbon group”, “optionally substituted aromatic heterocyclic group” and “substituted Examples of the substituent in the non-aromatic heterocyclic group j which may be substituted include, for example, alkyl having 1 to 6 carbon atoms which may be substituted by 1 to 3 halogen atoms (eg, fluorine, chlorine, bromine, iodine, etc.). Group, 1 to 3 halogen atoms (e.g., fluorine, chlorine, bromine, iodine, etc.), C2 to C6 alkenyl group, C3 to C10 cycloalkyl group which may be substituted by An aryl group having 6 to 14 carbon atoms (eg, phenyl, naphthyl, etc.), an aromatic heterocyclic group (eg, chenyl, furyl, pyridyl, oxazolyl, thiazolyl, etc.), a non-aromatic heterocyclic group (eg, Eg, tetrahydrofuryl, morpholino, thio Ruholino, piperidino, pyrrolidiel, piperazinyl, etc.), aralkyl group having 7 to 9 carbon atoms, amino group, alkyl group having 1 to 4 carbon atoms, or acyl group having 2 to 8 carbon atoms (eg, alkanoyl group, etc.). Di-substituted amino group, amidino group, C 2 -C 8 acyl group (eg, alkanoyl group, etc.), carbamoyl group, carbamoyl group mono- or di-substituted with C 1-4 alkyl group, sulfamoyl Group, a sulfamoyl group mono- or di-substituted by an alkyl group having 1 to 4 carbon atoms, Carboxyl group, alkoxycarbonyl group having 2 to 8 carbon atoms, hydroxy group, 1 to 3 carbon atoms which may be substituted with 1 to 3 halogen atoms (eg, fluorine, chlorine, bromine, iodine, etc.) An alkoxy group, an alkenyloxy group having 2 to 5 carbon atoms which may be substituted by 1 to 3 halogen atoms (eg, fluorine, chlorine, bromine, iodine, etc.), a cycloalkyloxy having 3 to 7 carbon atoms Group, C7-C9 aralkyloxy group, C6-C14 aryloxy group (e.g., phenyloxy, naphthyloxy, etc.), thiol group, 1-3 halogen atoms (e.g., fluorine, chlorine, bromine , Iodine, etc.) which may be substituted with an alkylthio group having 1 to 6 carbon atoms, an aralkylthio group having 7 to 9 carbon atoms, an arylthio group having 6 to 14 carbon atoms (eg, phenylthio, naphthylthio, etc.) , Examples include a ruho group, a cyano group, an azido group, a nitro group, a nitroso group, and a halogen atom (eg, fluorine, chlorine, bromine, iodine). The number of substituents is, for example, 1 to 3.

The "Ashiru group", for example Ashiru group having a carbon number of 1 to 13, other ho mill specifically, the formula: A ^{COR 11, - SOsR 11, -} SOR 11 or - P0 ₃ X ¹ R ¹² [wherein , R ¹¹ and R ¹² are the same or different; each represents a hydrocarbon group which may be substituted or an aromatic heterocyclic group which may be substituted], and the like.

As the “optionally substituted hydrocarbon group” for R ¹¹ or R ¹² , for example, those exemplified as the aforementioned R ¹ can be mentioned. The hydrocarbon group is preferably an alkyl group having 1 to 8 carbon atoms, a cycloalkyl group having 3 to 7 carbon atoms, an alkenyl group having 2 to 8 carbon atoms, a cycloalkenyl group having 5 to 7 carbon atoms, There are 14 groups.

As the “optionally substituted aromatic heterocyclic group” for R ¹¹ or R ¹² , for example, those exemplified as the substituent for the aforementioned R ¹ can be mentioned. The aromatic heterocyclic group is preferably phenyl, furyl or pyridyl.

The substituents in the “optionally substituted hydrocarbon group” and the “optionally substituted aromatic heterocyclic group” for R ¹¹ or R ¹² are preferably 1 to 3 halogen atoms (eg, , Fluorine, chlorine, bromine, iodine, etc.) optionally substituted Ci-s alkyl group, 1-3 halogen atoms (eg, fluorine, chlorine, odor, etc.) , Iodine, etc.). D alkoxy group, halogen atom

(Eg, fluorine, chlorine, bromine, iodine, etc.), nitro group, hydroxy group, and amino group. The number of substituents is, for example, 1 to 3.

 Preferable examples of the acryl group include, for example, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, heptanoyl, octanoyl, cyclobutanyl carbonyl, cyclopentane carbonyl, cyclohexane carbonyl, cycloheptanyl Examples include ketoluponyl, crotonyl, 2-cyclohexenecarbonyl, benzoyl, nicotinol, and isonicotinoyl.

Examples of the “optionally substituted amino group” include an alkyl group having 1 to 10 carbon atoms, an alkenyl group having 2 to 10 carbon atoms, a cycloalkyl group having 3 to 10 carbon atoms, and a carbon atom having 3 to 1 carbon atoms. Examples thereof include an amino group which may be mono- or di-substituted by a cycloalkenyl group having 0, an aryl group having 6 to 14 carbon atoms or an acyl group having 1 to 13 carbon atoms. Examples of these groups include those exemplified above as the substituent for R ¹ . Further, the C 1 to C 13 acyl group is preferably a C 2 to C 10 alkanol group, a C 7 to C 13 arylcarbonyl group or the like.

 Preferred examples of the substituted amino group include methylamino, dimethylamino, ethylamino, acetylamino, propylamino, dibutylamino, diarylamino, cyclohexylamino, acetylamino, propionylamino, benzoylamino, phenylamino, N-methyl-N-phenylamino, and the like. No.

Examples of the “optionally substituted hydroxy group” include, for example, an optionally substituted alkyl group having 1 to 10 carbon atoms, an alkenyl group having 2 to 10 carbon atoms, and a carbon number? And an aralkyl group having 1 to 13 carbon atoms, an acyl group having 1 to 13 carbon atoms, and a hydroxy group which may be substituted with an aryl group having 6 to 14 carbon atoms. Examples of the alkyl group, alkenyl group, acyl group or aryl are those exemplified above as the substituent for R ¹ . Examples of the aralkyl group include those exemplified as R ¹ above. These “alkyl groups having 1 to 10 carbon atoms”, “alkenyl groups having 2 to 10 carbon atoms”, “aralkyl groups having 7 to 13 carbon atoms”, “acyl groups having 1 to 13 carbon atoms” and “ Examples of the substituent which the aryl group having 6 to 14 carbon atoms may have are, for example, octylogen atom (eg, fluorine, chlorine, bromine, iodine, etc.), and 1 to 3 halogen atoms (eg, fluorine , chlorine, bromine, optionally substituted C ^ etc.) iodine - ₆ alkoxy group, hydroxy group, a nitro group, an amino group, and the like. The number of substituents is, for example, 1 or 2.

 Examples of the substituted hydroxy group include an optionally substituted alkoxy group, an alkenyloxy group, a cycloalkyloxy group, a cycloalkenyloxy group, an aralkyloxy group, an acyloxy group, an aryloxy group, and the like.

 Preferable examples of the alkoxy group include an alkoxy group having 1 to 10 carbon atoms, for example, methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec.-butoxy, t.-butoxy, pentyloxy, isopentyloxy, neo Pentyloxy, hexyloxy, heptyloxy, nonyloxy and the like.

 Preferable examples of the alkenyloxy group include an alkenyloxy group having 2 to 10 carbon atoms, such as allyloxy, crotyloxy, 2-pentenyloxy, and 3-hexenyloxy.

 Preferable examples of the cycloalkyloxy group include a cycloalkyloxy group having 3 to 7 carbon atoms, such as cyclobutoxy, cyclopentyloxy, and cyclohexyloxy.

 Preferable examples of the cycloalkenyloxy group include a cycloalkenyloxy group having 5 to 7 carbon atoms, such as 2-cyclopentenyloxy and 2-cyclohexenyloxy.

Preferable examples of Ararukiruokishi groups, Ararukiruo alkoxy group number 7-1 0 carbon atoms, for example phenylene Lou C Bok ₄ Arukiruokishi (eg, Benjiruokishi, Hue, etc. Nechiruokishi) and the like.

Preferred examples of the acyloxy group include an alkoxy group having 2 to 13 carbon atoms, More preferably, they include C 2-4 alkenyloxy (eg, acetyloxy, propionyloxy, petyryloxy, isoptyryloxy, etc.).

 Preferable examples of the aryloxy group include an aryloxy group having 6 to 14 carbon atoms, such as phenoxy and naphthyloxy.

 The alkoxy group, alkenyloxy group, cycloalkyloxy group, cycloalkenyloxy group, aralkyloxy group, acyloxy group and aryloxy group have one or two substituents at substitutable positions. Examples of such a substituent include, for example, a halogen atom (eg, fluorine, chlorine, bromine, iodine, etc.) and one to three halogen atoms (eg, fluorine, chlorine, bromine, iodine, etc.). And an alkoxy group, a hydroxy group, a nitro group, an amino group and the like.

Examples of the optionally substituted thiol group include an alkyl group having 1 to 10 carbon atoms, a cycloalkyl group having 3 to 10 carbon atoms, an aralkyl group having 7 to 13 carbon atoms, and a carbon atom having 1 to 10 carbon atoms. And a thiol group which may be substituted with an aryl group having 13 to 13 carbon atoms, an aryl group having 6 to 14 carbon atoms, or a heteroaryl group. Examples of the alkyl group, cycloalkyl group, acyl group and aryl group include those exemplified as the substituent for R ¹ . Examples of the aralkyl group include those exemplified as the aforementioned R ¹ .

 Preferred examples of the heteroaryl group include pyridyl (eg, 2-pyridyl, 3-pyridyl), imidazolyl (eg, 2-imidazolyl), triazolyl (eg, 1,2,4-triazole-5-yl) and the like. Can be

 Examples of the substituted thiol group include alkylthio, cycloalkylthio, aralkylthio, acylthio, arylthio, and heteroarylthio.

Preferable examples of the alkylthio group include an alkylthio group having 1 to 10 carbon atoms, such as methylthio, ethylthio, propylthio, isopropylthio, butylthio, isobutylthio, sec. Butylthio, t. Butylthio, pentylthio, isopentylthio. , Neopentylthio, hexylthio, heptylthio, noni Luthio and the like.

 Preferable examples of the cycloalkylthio group include a cycloalkylthio group having 3 to 10 carbon atoms, for example, cyclobutylthio, cyclopentylthio, cyclohexylthio and the like.

Preferable examples of Ararukiruchio group, Ararukiruchio group having a carbon number of 7 to 0, for example, phenylene Lu ^ _ ₄ alkylthio (e.g., benzylthio, Fuenechiruchi O, etc.) and the like.

 Preferable examples of the acylthio group include an acylthio group having 2 to 13 carbon atoms, more preferably an alkanolthio group having 2 to 4 carbon atoms (eg, acetylthio, propionylthio, butyrylthio, isobutyrylthio, etc.). . Preferable examples of arylthio groups include arylthio groups having 6 to 14 carbon atoms, such as phenylthio and naphthylthio.

 Preferable examples of the heteroarylthio group include pyridylthio (eg, 2-pyridylthio, 3-pyridylthio), imidazolylthio (eg, 2-imidazolylthio), triazolylthio (eg, 1,2,4-triazolylthio). Lou 5-ylthio) and the like.

 In the optionally substituted ester group, the esterified ester group may be, for example, an alkoxyl group having 2 to 5 carbon atoms (e.g., methoxycarbonyl, ethoxycarbonyl, propoxylponyl, ptoxycarponyl, etc.). An aralkyloxycarbonyl group having 8 to 10 carbon atoms (e.g., benzyloxycarbonyl, etc.), an alkyl group having 7 to 15 carbon atoms which may be substituted with 1 to 2 alkyl groups having 1 to 3 carbon atoms. And a ryloxycarbonyl group (eg, phenoxycarbonyl, p-tolyloxycarbonyl) and the like.

In the optionally amidated carbonyl group, the amidated carboxyl group may be represented by the formula: —CON (R ¹³ ) (R ¹⁴ )

(Wherein, R ¹³ and R ¹⁴ are the same or different and each represent a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, and R ¹³ and R ^{13 14} forms a nitrogen-containing heterocyclic ring which may be substituted with an adjacent nitrogen atom. May be formed. ).

Here, the "optionally substituted hydrocarbon group" and "optionally substituted heterocyclic group" represented by R ^{1 3} and R ^{1 4} are include those exemplified as the R ^1. The substituents on the hydrocarbon group and the heterocyclic group are preferably a halogen atom (eg, fluorine, chlorine, bromine, iodine, etc.), and 1 to 3 halogen atoms (eg, fluorine, chlorine, bromine, iodine) (^ -6 alkyl group, 1 to 3 halogen atoms (eg, fluorine, chlorine, bromine, iodine, etc.) alkoxy group, nitro group And the number of substituents is, for example, 1 to 3.

As the "nitrogen-containing heterocycle" of R ^{1 3} and R ^{1 4} is formed together with the adjacent nitrogen atom "nitrogen-containing heterocyclic ring but it may also be substituted", for example, as a ring-constituting atom, besides carbon atoms Examples thereof include a 5- to 7-membered nitrogen-containing heterocyclic ring which contains at least one nitrogen atom and may further contain 1 to 3 hetero atoms selected from an oxygen atom, a sulfur atom and a nitrogen atom. The “nitrogen-containing heterocycle” is preferably piperidine, morpholine, thiomorpholine, piperazine, pyrrolidine and the like.

 As the “substituent” in the “optionally substituted nitrogen-containing heterocycle”, those exemplified as the “substituent” in the aforementioned “optionally substituted alicyclic hydrocarbon group” and the like are used. Can be The number of substituents is, for example, 1 to 3.

Preferred examples of the substituent for R ¹ include:

 1) An alkoxy group having 1 to 6 carbon atoms which may be substituted with 1 to 3 halogen atoms (eg, fluorine, chlorine, bromine, iodine, etc.), a halogen atom (eg, fluorine, chlorine, bromine, iodine, etc.) ) An alkyl group having 1 to 10 (preferably 1 to 4) carbon atoms which may have 1 to 3 substituents selected from nitro, hydroxy and amino groups (preferably methyl, ethyl, etc.) );

2) An alkyl group having 1 to 6 carbon atoms which may be substituted by 1 to 3 halogen atoms (eg, fluorine, chlorine, bromine, iodine, etc.), a 1 to 3 halogen atom (eg, fluorine, C1-C6 alkoxy groups and halogen atoms (eg, fluorine, chlorine, odor) which may be substituted with chlorine, bromine, iodine, etc. , A nitro group, a hydroxy group and an amino group, which may have 1 to 3 substituents, and may have 3 to 10 (preferably 3 to 7) cycloalkyl groups (preferably Is cyclohexyl);

 3) An alkyl group having 1 to 6 carbon atoms which may be substituted by 1 to 3 halogen atoms (eg, fluorine, chlorine, bromine, iodine, etc.), 1 to 3 halogen atoms (eg, fluorine, Selected from C1-C6 alkoxy groups, halogen atoms (eg, fluorine, chlorine, bromine, iodine, etc.), nitro groups, hydroxy groups and amino groups, which may be substituted with chlorine, bromine, iodine, etc. An aryl group having 6 to 14 carbon atoms which may have 1 to 3 substituents (preferably phenyl, naphthyl, etc.);

4) An alkyl group having 1 to 6 carbon atoms which may be substituted by 1 to 3 halogen atoms (eg, fluorine, chlorine, bromine, iodine, etc.), 1 to 3 halogen atoms (eg, fluorine, Selected from C1-C6 alkoxy groups, halogen atoms (eg, fluorine, chlorine, bromine, iodine, etc.), nitro groups, hydroxy groups and amino groups, which may be substituted with chlorine, bromine, iodine, etc. Aromatic heterocyclic groups which may have 1 to 3 substituents (preferably furyl, phenyl, pyridyl, pyridinyl and the like); and the like. The number of substituents in R ¹ is preferably 1 to 3, more preferably 1 or 2. In the general formula (I), R ¹ is preferably an optionally substituted cyclic group. Examples of the cyclic group include the aforementioned cyclic hydrocarbon group and heterocyclic group. R ¹ is more preferably an optionally substituted heterocyclic group (preferably an aromatic heterocyclic group).

Preferred specific examples of R ¹ include:

 1) An alkoxy group having 1 to 6 carbon atoms which may be substituted with 1 to 3 halogen atoms (eg, fluorine, chlorine, bromine, iodine, etc.), a halogen atom (eg, fluorine, chlorine, bromine, iodine, etc.) ) An alkyl group having 1 to 10 (preferably 1 to 4) carbon atoms which may have 1 to 3 substituents selected from nitro, hydroxy and amino groups (preferably methyl, ethyl, etc.) );

2) 1 to 3 halogen atoms (eg, fluorine, chlorine, bromine, iodine, etc.) An alkyl group having 1 to 6 carbon atoms which may be substituted by 1 to 3 carbon atoms which may be substituted by 1 to 3 halogen atoms (eg, fluorine, chlorine, bromine, iodine, etc.) C3-C10 which may have 1 to 3 substituents selected from an alkoxy group, a halogen atom (eg, fluorine, chlorine, bromine, iodine, etc.), a nitro group, a hydroxy group and an amino group. (Preferably 3 to 7) cycloalkyl groups (preferably cyclohexyl);

3) An alkyl group having 1 to 6 carbon atoms which may be substituted by 1 to 3 halogen atoms (eg, fluorine, chlorine, bromine, iodine, etc.), 1 to 3 halogen atoms (eg, fluorine, Selected from C1-C6 alkoxy groups, halogen atoms (eg, fluorine, chlorine, bromine, iodine, etc.), nitro groups, hydroxy groups and amino groups, which may be substituted with chlorine, bromine, iodine, etc. An aryl group having 6 to 14 carbon atoms which may have 1 to 3 substituents (preferably, phenyl, naphthyl, etc.); and

 4) An alkyl group having 1 to 6 carbon atoms which may be substituted by 1 to 3 halogen atoms (eg, fluorine, chlorine, bromine, iodine, etc.), 1 to 3 halogen atoms (eg, fluorine, Selected from C1-C6 alkoxy groups, halogen atoms (eg, fluorine, chlorine, bromine, iodine, etc.), nitro groups, hydroxy groups and amino groups, which may be substituted with chlorine, bromine, iodine, etc. An aromatic heterocyclic group optionally having 1 to 3 substituents (preferably furyl, phenyl, pyridyl, pyrazinyl, etc.); and optionally having 1 to 3 substituents selected from 5- to 7-membered monocyclic aromatic heterocyclic group (preferably oxazolyl, thiazolyl, oxdiazolyl, thiadiazolyl, triazolyl, pyridyl, etc .; more preferably oxazolo Le, etc.) and the like.

Among them, an alkyl group having 1 to 4 carbon atoms (preferably methyl, ethyl, etc.), an aryl group having 6 to 14 carbon atoms (preferably phenyl, naphthyl, etc.) and an aromatic heterocyclic group (preferably furyl, A 5- to 7-membered monocyclic aromatic heterocyclic group (preferably oxazolyl, thiazolyl, oxazidiazolyl) which may have 1 to 3 substituents selected from phenyl, pyridyl, pyrazinyl and the like. Thiadiazolyl, triazolyl, pyridyl, etc .; more preferred Or oxazolyl). In the general formula (I), X and Y are the same or different bond, an oxygen atom, sulfur atom, -CO-, one CS-, one ^{_{S_〇-, -S0 2 -, -CR 3 (}} OR 4) —, NR ⁵ —, — CONR ⁶ — or — NR ⁶ C—— (R ³ is a hydrogen atom or an optionally substituted hydrocarbon group, R ⁴ is a hydrogen atom or a hydroxyl-protecting group, R ⁵ Represents a hydrogen atom, an optionally substituted hydrocarbon group or an amino group-protecting group, and R ⁶ represents a hydrogen atom or an optionally substituted hydrocarbon group.

X is preferably a bond, an oxygen atom, a sulfur atom, —CO—, one CS—, one CR ³ (OR ⁴ ) one or —NR ⁵ — (R ³ , R ⁴ and R ⁵ are as defined above. More preferably a bond or —NR ⁵ _ (R ⁵ has the same meaning as described above); particularly preferably a bond.

As the “optionally substituted hydrocarbon group” represented by R ³ and R ⁵ , those exemplified as the aforementioned R ¹ can be mentioned. The `` optionally substituted hydrocarbon group '' is preferably an optionally substituted alkyl group having 1 to 4 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec. -Butyl, t.-butyl and the like. The alkyl group may have 1 to 3 substituents at substitutable positions. Examples of such a substituent include an octogen atom (eg, fluorine, chlorine, bromine, iodine), carbon Alkoxy groups of 1 to 4 (eg, methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec.-butoxy, t.-butoxy, etc.), hydroxy group, nitro group, amino group, 1 to 4 carbon atoms And acyl groups (eg, alkanoyl groups having 1 to 4 carbon atoms such as formyl, acetyl, propionyl, etc.).

R ³ and R ⁵ are preferably a hydrogen atom or an alkyl having 1 to 4 carbons.

As the protective group for the hydroxyl group represented by R ^4, for example, (vii ₆ alkyl (e.g., methylation, Echiru, propyl, isopropyl, heptyl, tert such as single heptyl), phenyl, trityl, C ₇ _ ₁₀ Ararukiru (e.g., Benzyl, etc.), formyl, ^ Alkyl-carbonyl (eg, acetyl, propionyl, etc.), benzoyl,. Aralkyl-carbonyl (eg, benzylcarbonyl, etc.), 2-tetrahydropyrael, 2-tetrahydrofuranyl, silyl (eg, trimethylsilyl, triethylsilyl, dimethylphenylsilyl, tert-butyldimethylsilyl, tert-butylethylsilyl, etc.) , C ₂ _ ₆ alkenyl (eg, 1-aryl) and the like. These groups include one to three halogen atoms (eg, fluorine, chlorine, bromine, iodine, etc.), C- ₆ alkyl (eg, methyl, ethyl, propyl, etc.), ₆ alkoxy (eg, methoxy, ethoxy, Or a nitro group.

The protecting group of the Amino group represented by R ^5, for example formyl, (Bok ₆ alkylene Lou carbonyl (e.g., Asechiru, propionyl and the like), C ^ - ₆ alkoxy Ichiriki Ruponiru (e.g., methoxy Cal Poni Le, ethoxy Cal Poni Le, tert- but-like Kishikaruponiru) Benzoiru, C ₇ _ i Ararukiru -. power Ruponiru (eg, benzyl Cal Poni Le), C ₇ _ ₁₄ Ararukiruokishi one carbonyl (e.g., base Njiruokishi force Ruponiru and 9 one full O Les methoxy Cal Poni Le) , Bok rutile, phthaloyl, N, N-dimethylaminomethylene, silyl (e.g., trimethylsilyl, triethylsilyl, dimethyl-phenylalanine silyl, tert- Bed chill butyldimethylsilyl, tert one Petit Rougier chill silyl, etc.), C ₂ - ₆ alkenyl Nil (eg, 1-aryl) etc. These groups are May be substituted with 1 to 3 halogen atoms (eg, fluorine, chlorine, bromine, iodine, etc.), ₆ alkoxy (eg, methoxy, ethoxy, propoxy, etc.), or a nitro group.

As the “optionally substituted hydrocarbon group” for R ⁶ , those exemplified for the aforementioned R ¹ can be mentioned. Among them, an alkyl group having 1 to 4 carbon atoms is preferable. R ⁶ is preferably a hydrogen atom.

Y is preferably a bond, an oxygen atom, a sulfur atom, — SO_, one S〇 ₂ —, -N 6-one CONR ⁶ — or one NR ⁶ C〇, (: R ⁶ is a hydrogen atom or a substituted More preferably an oxygen atom or one NR ⁶ — (R ⁶ has the same meaning as described above); particularly preferably an oxygen atom. In the general formula (I), examples of the “divalent hydrocarbon group having 1 to 20 carbon atoms” represented by Q include “divalent acyclic hydrocarbon group” and “divalent cyclic hydrocarbon”. And a divalent group obtained by combining one or more divalent acyclic hydrocarbon groups with one or more divalent cyclic hydrocarbon groups.

 Here, examples of the “divalent acyclic hydrocarbon group” include alkylene having 1 to 20 carbon atoms, alkenylene having 2 to 20 carbon atoms, and alkynylene having 2 to 20 carbon atoms. .

 As the `` divalent cyclic hydrocarbon group '', there may be mentioned a cycloalkane having 5 to 20 carbon atoms, a cycloalkene having 5 to 20 carbon atoms or an aromatic hydrocarbon having 6 to 18 carbon atoms (e.g., benzene, And a divalent group obtained by removing any two hydrogen atoms from naphthalene, indene, and anthracene. Specific examples include 1,2-cyclopentylene, 1,3-cyclopentylene, 1,2-cyclohexylene, 1,3-cyclohexylene, 1,4-cyclohexylene, and 1,2-cyclohexylene. Butylene, 1,3-cycloheptylene, 1,4-cyclohexene, 3-cyclohexene-1,4-ylene, 3-cyclohexene-1,2-ylene, 2,5-cyclohexagen-1, 4-pyrene, 1,2-phenylene, 1,3-phenylene, 1,4-phenylene, 1,4-naphthylene, 1,6-naphthylene, 2,6-naphthylene, 2,7-one Examples include naphthylene, 1,5-indenylene, and 2,5-indenylene.

Q is preferably a divalent hydrocarbon group having 1 to 6 carbon atoms, and among them, (DC ₆ alkylene (for example, —C—, mono (CH ₂ ) ₂ —,-(CH ₂ ) ₃ —, _ (CH ₂ ) ₄ one, one (CH ₂ ) ₅ —, one (CH ₂ ) ₆ —, one CH (C¾) —, one C (CH ₃ ) ₂ —, one (CH (CH ₃ )) ₂ —, One (CH ₂ ) ₂ C (CH ₃ ) ₂ —,-(CH ₂ ) 3 C (CH ₃ ) ₂ etc.);

(2) C ₂ _ ₆ alkenylene (eg, _CH = CH—, one CH ₂ _CH = CH—, one C (CH ₃ ) ₂ — CH = CH—, — CH ₂ — CH = CH—CH ₂ —, — C¾— CH ₂ — CH = CH—, one CH = CH— CH = CH—, — CH = CH— CH ₂ — C¾— C—, etc.);

(3) C ₂ - ₆ alkynylene (e.g., - C [identical to] C one, - C¾ _C≡C-, such as -CH ₂ -C≡C-CH ₂ one CH ₂ I) and the like are preferable. Q is more preferably a C alkylene or C ₂ _ ₆ alkenylene, among others, one _{CH 2 -, - (CH 2} ) 2 -, - (CH 2) 3 -, - (CH 2) 4 -, - CH-CH— and the like are preferable. Q is particularly preferably —CH ₂ —, — (CH ₂ ) ₂ — and the like. In the general formula (I), the “aromatic ring” in the “aromatic ring optionally having one to three substituents” represented by ring A includes, for example, a benzene ring, a condensed aromatic hydrocarbon Ring, 5- or 6-membered aromatic heterocyclic ring, condensed aromatic heterocyclic ring and the like.

 Here, the “condensed aromatic hydrocarbon ring” includes, for example, a condensed aromatic hydrocarbon ring having 9 to 14 carbon atoms. Specific examples include naphthalene, indene, fluorene, and anthracene.

 Examples of the "5- or 6-membered aromatic heterocycle" include a 5- or 6-membered aromatic heterocycle containing 1 to 3 heteroatoms selected from nitrogen, sulfur and oxygen atoms in addition to carbon atoms. Can be Specifically, thiophene, furan, pyrrol, imidazole, pyrazole, thiazole, isothiazol, oxazole, isoxazole, pyridine, pyrazine, pyrimidine, pyridazine, 1,2,4-oxaziazol, 1,3 , 4-oxadiazole, 1,2,4-thiadiazole, 1,3,4-thiadiazole, furazane and the like.

 As the “fused aromatic heterocycle”, for example, a 9 to 14 membered (preferably 9 or 10 membered) containing 1 to 4 hetero atoms selected from a nitrogen atom, a sulfur atom and an oxygen atom in addition to a carbon atom And fused aromatic heterocycles. Specifically, benzofuran, benzothiophene, benzimidazole, benzoxazole, benzothiazole, benzisothiazole, naphtho [2,3-b] thiophene, isoquinoline, quinoline, indole, quinoxaline, phenanthidine, phenothiazine Phenoxazine, phthalazine, naphthyridin, quinazoline, cinnoline, carbazole, / 3-butanol, acridine, phenazine, phthalimide and the like.

The “aromatic ring” is preferably a benzene ring, a condensed aromatic hydrocarbon ring having 9 to 14 carbon atoms (preferably naphthalene or the like), a 5- or 6-membered aromatic heterocyclic ring (preferably Preferably, pyridine, oxazole, isoxazole, thiazole, oxdiazole, etc.).

As the `` substituent '' in the `` aromatic ring which may further have 1 to 3 substituents '' for ring A, an optionally substituted aliphatic hydrocarbon group, an optionally substituted Examples include a good hydroxy group, a halogen atom, an acyl group, a nitro group, and an optionally substituted amino group. As each of these substituents, those exemplified as the substituent for R ¹ can be used. The substituent in the ring A is preferably an alkyl group having 1 to 4 carbon atoms, a hydroxy group, an alkoxy group having 1 to 4 carbon atoms (preferably methoxy), an aralkyloxy group having 7 to 10 carbon atoms, or an octylogen atom. is there.

 Ring A preferably has 1 or 2 substituents selected from an alkyl group having 1 to 4 carbon atoms, a hydroxy group, an alkoxy group having 1 to 4 carbon atoms (preferably methoxy) and a halogen atom. A benzene ring or a 5- or 6-membered aromatic heterocyclic ring (preferably pyridine); more preferably a benzene ring or a benzene ring optionally substituted with an alkoxy group having 1 to 4 carbon atoms (preferably methoxy); It is a 5- or 6-membered aromatic heterocycle (preferably pyridine). In the general formula (I), n represents an integer of 1 to 8. n is preferably an integer of 1 to 3, and more preferably 1. In the general formula (I), the “nitrogen-containing 5-membered heterocyclic ring” represented by ring B includes, for example, at least one nitrogen atom other than a carbon atom as a ring-constituting atom, and includes an oxygen atom, a sulfur atom, and a nitrogen atom. And a 5-membered heterocyclic ring which may further contain 1 to 3 heteroatoms selected from

Preferred examples of the "nitrogen-containing 5-membered heterocycle" include nitrogen-containing 5-membered non-aromatic heterocycles such as pyrrolidine, imidazolidine, pyrazolidine, 1,3-oxazolidine, 1,3-thiazolidine, isoxazolidine, and isothiazolidine. ; Nitrogen-containing 5-members such as pyrrole, imidazole, pyrazole, triazole, and tetrazole An aromatic heterocycle is mentioned.

 The “nitrogen-containing 5-membered heterocycle” represented by ring B is preferably a nitrogen-containing 5-membered aromatic complex ring, and more preferably a pyrrole ring, an imidazole ring, a pyrazoyl ring and the like.

 Ring B may have 1 to 3, preferably 1 to 2 substituents at substitutable positions. Such substituents include, for example, "octogen",

“Nitro group”, “optionally substituted hydrocarbon group (preferably, aliphatic hydrocarbon group, alicyclic hydrocarbon group, aromatic hydrocarbon group)”, “optionally substituted aromatic group” "Heterocyclic group", "optionally substituted non-aromatic heterocyclic group", "acyl group", "optionally substituted amino group", "optionally substituted hydroxy group", " Thiol group which may be substituted "," carboxyl group which may be esterified or amidated "and the like. As these substituents, those exemplified as the substituent for R ¹ can be used. In the formula (I), ring B, wherein: - Wa- (C = 0) - a divalent hydrocarbon residue R ^a (Wa to not bond or carbon number 1 2 0, the R ^a - 0R ^b (R ^b represents a hydrogen atom or a hydrocarbon group which may be substituted) or one NR ^d (R ^e and R ^d are the same or different and a hydrogen atom, a hydrocarbon group which may be substituted, Represents an optionally substituted heterocyclic group or a substituted or optionally substituted acyl group, and IT and R ^d may be bonded to form a ring). No.

 The “substituent” in ring B is preferably a hydrocarbon group, more preferably an alkyl group having 1 to 10 carbon atoms (preferably methyl or the like), an aralkyl group having 7 to 13 carbon atoms (eg, Benzyl, etc.) and aryl groups having 6 to 14 carbon atoms (preferably phenyl, naphthyl, etc.).

 Further, as the “substituent” in ring B, a monocyclic aromatic heterocyclic group (preferably, furyl or phenyl) is also preferable.

Ring B preferably has one or two substituents selected from an aryl group (preferably phenyl) having 6 to 14 carbon atoms and a monocyclic aromatic heterocyclic group (preferably furyl, phenyl). 5-membered aromatic heterocycle (optional) Or a pyrrol ring, an imidazole ring, or a pyrazole ring, and more preferably a pyrrol ring or a pyrazole ring). In the general formula (I), examples of the “divalent hydrocarbon group having 1 to 20 carbon atoms” represented by W include those exemplified as the aforementioned Q. W is preferably C _ ₆ alkylene or C ₂ _ ₆ alkenylene, among others, single C -! One (CH _{2) 2 one, - (CH 2) 3 -} , - (CH 2) 4 -, - CH = CH— and the like are preferable. W is particularly preferably —CH ₂ —, — (CH ₂ ) ₂ —, —CH = CH—, and the like. In the general formula (I), V is a bond, an oxygen atom, a sulfur atom, One S_〇 one one S_〇 ₂ one, - NR ⁷ - or a NR ⁷ CO- (R ⁷ is is hydrogen atom or a substituent Represents a hydrocarbon group which may be present).

As the “optionally substituted hydrocarbon group” for R ⁷ , those exemplified for the aforementioned R ¹ can be mentioned. Among them, an alkyl group having 1 to 4 carbon atoms is preferable. R ⁷ is preferably a hydrogen atom. , V is preferably a bond. In the general formula (I), R ² is one ^{PO (OR 8) (OR 9} ) (R 8 and R ⁹ represents a hydrocarbon group which may optionally be a hydrogen atom or a substituent same or different, and R ⁸ And R ⁹ may combine to form an optionally substituted ring), -COR ¹⁰ (R ^1Q represents a hydrogen atom or an optionally substituted carbon hydride group), A hydrocarbon group which may be substituted or a heterocyclic group which may be substituted.

Examples of the “optionally substituted carbon hydride group” represented by RR ⁹ , R ^1Q and R ² include those exemplified as the aforementioned R ¹ .

The “optionally substituted hydrocarbon group” represented by R ⁸ , 1 ^ ^{9 and} 11 ⁽⁾ is preferably an “alkyl group having 1 to 4 carbon atoms” and the like. Here, the “alkyl group having 1 to 4 carbon atoms” includes, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, t-butyl and the like. And methyl and ethyl are particularly preferred.

As the “optionally substituted heterocyclic group” for R ² , those exemplified for the aforementioned R ¹ can be mentioned. Among them, a 5- to 7-membered monocyclic aromatic heterocyclic group (preferably oxazolyl, thiazolyl, or the like) which may be substituted by an alkyl group having 1 to 4 carbon atoms (preferably methyl, ethyl, propyl) Oxaziazolyl, thiadiazolyl, triazolyl, pyridyl; more preferably thiazolyl, oxaziazolyl) and the like.

The “optionally substituted ring” formed by R ⁸ and; ⁹ together with an adjacent oxygen atom and phosphorus atom is, for example, a compound represented by the formula:

[In the formula, alk represents an alkylene group having 1 to 10 carbon atoms which may be substituted.] "Alkyl group having 1 to 10 carbon atoms which may be substituted" Examples of the “alkylene group of 10” include —C, — (CH ₂ ) ₂ —, one (CH ₂ ) ₃ —, one (CH ₂ ) ₄ —, _ (C) ₅ —, one (C¾) ₆ — , One CH (C) —, one C (CH ₃ ) ₂ one, one (CH (C)) ₂ —, one (C) ₂ C (C¾) ₂ —, one (C¾) ₃ C (C¾) ₂ — , -CH (CH ₃ ) -CH ₂ , — CH ₂ — CH (C) — C¾—, — CH ₂ — C (C) “C —, — C _ CH (CC) — C¾, -CH ( CH ₃ ) -CH ₂ -1 CH (CH ₃ ) 1 and the like.

 The “alkylene group having 1 to 10 carbon atoms” may have 1 to 3, preferably 1 to 2 substituents at substitutable positions. Examples of such a substituent include a hydroxyl group, a halogen atom (eg, fluorine, chlorine, bromine, iodine, etc.).

R ² is Konomareku one P_〇 ^{(OR 8) (OR 9)} (R 8 and R ⁹ represents a were identical or different and represent a hydrogen atom or an optionally substituted hydrocarbon group and R ⁸ And R ⁹ may combine to form an optionally substituted ring), -COR ¹⁰ (R ^{1 Q} represents a hydrogen atom or an optionally substituted hydrocarbon group) or A heterocyclic group which may be (OR ⁸ ) (OR ⁹ ) (R ⁸ and R ⁹ are as defined above) or an optionally substituted heterocyclic group.

R ² is particularly preferably

1) -PO (OR ⁸ ) (OR ⁹ ) [R ⁸ and R ⁹ are the same or different and are a hydrogen atom or an alkyl group having 1 to 4 carbon atoms (preferably methyl, ethyl, propyl)];

2) A 5- to 7-membered monocyclic aromatic heterocyclic group (preferably oxazolyl, thiazolyl) which may be substituted by an alkyl group having 1 to 4 carbon atoms (preferably methyl, ethyl, propyl). Oxadiazolyl, thiadiazolyl, triazolyl, pyridyl; more preferably thiazolyl, oxaziazolyl). In the formula (I), when V is a bond, R ² one ^{(C = 0) - R e} (R e one 0R ^f (R ^f is a hydrogen atom or an optionally substituted hydrocarbon group shown) or a NR¾ ^h (R ^g and R ^h are the same or different and each represents a hydrogen atom, an optionally substituted carbon hydrocarbon group, an optionally substituted heterocyclic group or optionally substituted §, And R ^g and R ^h may be combined to form a ring), but not a hydrocarbon group substituted with a substituent represented by the formula: Preferable specific examples of the compound represented by the general formula (I) include the following compounds.

R ¹ is an alkyl group having 1 to 4 carbon atoms (preferably methyl, ethyl, etc.), an aryl group having 6 to 14 carbon atoms (preferably phenyl, naphthyl, etc.) and an aromatic heterocyclic group (preferably furyl, phenyl, A 5- to 7-membered monocyclic aromatic heterocyclic group (preferably oxazolyl, thiazolyl, oxaziazolyl, thiadiazolyl, triazolyl) which may have 1 to 3 substituents selected from pyridyl, pyragel, etc. Pyridyl or the like; more preferably oxazolyl);

X is a bond; Q is C i _ ₆ alkylene or C ₂ - ₆ alkenylene (preferably - CH ₂ -, one (CH ₂₎

₂ — etc.);

 Y is an oxygen atom;

A ring A in which a benzene ring or a 5- or 6-membered aromatic heterocycle (preferably pyridine) each of which may be substituted by an alkoxy group having 1 to 4 carbon atoms (preferably methoxy);

n is an integer of 1 to 3 (preferably 1);

Ring B may have 1 to 2 substituents selected from an aryl group having 6 to 14 carbon atoms (preferably phenyl) and a monocyclic aromatic heterocyclic group (preferably furyl, phenyl). Good 5-membered aromatic heterocycle (preferably pyrrole ring, imidazole ring, pyrazolyl ring, more preferably pyrrole ring, pyrazolyl ring

W is C ₆ alkylene or C ₂ - ₆ alkenylene (preferably - CH ₂ -, one _{(C) 2 _, -CH =} CH-);

V is a bond;

 But

1) -PO (OR ⁸ ) (OR ⁹ ) [R ⁸ and R ⁹ are the same or different and are a hydrogen atom or an alkyl group having 1 to 4 carbon atoms (preferably methyl, ethyl, propyl)] or

2) A 5- to 7-membered monocyclic aromatic heterocyclic group (preferably oxazolyl or thiazolyl) which may be substituted by an alkyl group having 1 to 4 carbon atoms (preferably methyl, ethyl, or propyl). Oxadiazolyl, thiadiazolyl, triazolyl, pyridyl; more preferably thiazolyl, oxaziazolyl). As the salt of the compound represented by the general formula (I) (hereinafter may be abbreviated as the compound (I)), a pharmacologically acceptable salt is preferable. For example, a salt with an inorganic base, an organic base, And salts with inorganic acids, salts with organic acids, salts with basic or acidic amino acids, and the like. Preferable examples of the salt with an inorganic base include, for example, alkali metal salts such as sodium salt, potassium salt and lithium salt; alkaline earth metal salts such as calcium salt and magnesium salt; aluminum salt, ammonium salt and the like. . Preferred examples of salts with organic bases include, for example, trimethylamine, triethylamine, pyridine, picoline, ethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, N, N-dibenzylethylenediamine and the like. Salts.

 Preferable examples of salts with inorganic acids include salts with hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, and the like.

 Preferred examples of salts with organic acids include, for example, formic acid, acetic acid, trifluoroacetic acid, fumanoleic acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, P- Examples thereof include salts with toluenesulfonic acid and the like.

 Preferable examples of salts with basic amino acids include salts with arginine, lysine, orditin and the like. '

Preferable examples of the salt with an acidic amino acid include, for example, salts with aspartic acid, glutamic acid and the like. A prodrug of compound (I) is a compound that is converted into compound (I) by a reaction with an enzyme or stomach acid under physiological conditions in vivo, that is, a compound (I) that is enzymatically oxidized, reduced, hydrolyzed, etc. Or a compound that undergoes hydrolysis or the like due to stomach acid or the like to change to compound (I). Examples of the prodrug of compound (I) include compounds in which the amino group of compound (I) is acylated, alkylated, and phosphorylated (eg, the amino group of compound (I) is eicosanoylated, alanylated, pentylaminocarbonyl). , (5-methyl-2-oxo-1,1,3-dioxolen-141-yl) methoxycarbonylation, tetrahydrofuranylation, tetrahydrovinylation, pyrrolidylmethylation, bivaloyloxymethylation, tert-yl Compounds in which the hydroxyl group of compound (I) is acylated, alkylated, phosphorylated, or borated (eg, compound (I) Compounds in which the hydroxyl group of acetylation, palmitoylation, propanoylation, piperoylation, succinylation, fumarylation, aranylation, dimethylaminomethylcarbonylation, tetrahydropyranylation, etc.); carboxyl group of compound (I) Is an esterified or amidated compound (eg, the carboxyl group of compound (I) is ethylesterified, phenylesterified, carboxymethylesterified, dimethylaminomethylesterified, pivaloyloxymethylesterified) , Ethoxycarponyloxetyl esterification, phthalidyl esterification,

(5-methyl-2-oxo-11,3-dioxolen-41yl) methyl esterified, cyclohexyloxycarponylethyl esterified, methylamidated compounds, etc.). These compounds can be produced from compound (I) by a method known per se.

 In addition, the prodrug of compound (I) can be obtained under physiological conditions as described in Hirokawa Shoten, 1990, “Development of Drugs,” Vol. 7, Molecular Design, pp. 163 to 198. (I) may be changed.

The compound (I) may be labeled with an isotope (eg,% ^H C, ³⁵ S, I ²⁵ I, etc.).

 Further, the compound (I) may be an anhydride or a hydrate. Compound (I) or a salt thereof (hereinafter may be simply abbreviated as the compound of the present invention) has a low toxicity and is used as it is or as a mixture with a pharmacologically acceptable carrier to form a pharmaceutical composition. As a result, it can be used as a preventive / therapeutic agent for various diseases described below in mammals (eg, humans, mice, rats, puppies, dogs, cats, cats, puppies, pigs, monkeys, etc.). .

Here, as the pharmacologically acceptable carrier, various organic or inorganic carrier substances commonly used as drug substances are used, and excipients, lubricants, binders, disintegrants in solid preparations, and solvents in liquid preparations It is formulated as a solubilizer, suspending agent, isotonic agent, buffer, soothing agent and the like. If necessary, pharmaceutical additives such as preservatives, antioxidants, coloring agents and sweeteners can also be used. Preferred examples of excipients include lactose, sucrose, D-mannitol, D- Sorbitol, starch, pregelatinized starch, dextrin, crystalline cellulose, low-substituted hydroxypropylcellulose, sodium carboxymethylcellulose, gum arabic, dextrin, pullulan, light silicic anhydride, synthetic aluminum silicate, magnesium aluminate metasilicate, etc. Is mentioned. Preferred examples of the lubricant include, for example, magnesium stearate, calcium stearate, talc, colloidal silica and the like.

 Preferred examples of the binder include, for example, starch arsenide, sucrose, gelatin, arabia gum, methylcellulose, carboxymethylcellulose, carboxymethylcellulose sodium, crystalline cellulose, sucrose, D-mannitol, trehalose, dextrin, pullulan, hydroxy Propylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone and the like.

 Preferred examples of the disintegrant include, for example, lactose, sucrose, starch, lipoxymethylcellulose, carboxymethylcellulose calcium, croscarmellose sodium, carboxymethylstarch sodium, light citric anhydride, low-substituted hydroxypropylcellulose and the like. Can be

 Preferred examples of the solvent include water for injection, physiological saline, Ringer's solution, alcohol, propylene glycol, polyethylene glycol, sesame oil, corn oil, olive oil, cottonseed oil and the like.

 Preferable examples of the solubilizing agent include, for example, polyethylene glycol, propylene glycol, D-manni! ^ L, trehalose, benzyl benzoate, ethanol, trisaminomethane, cholesterol, triethanolamine, Examples include sodium carbonate, sodium citrate, sodium salicylate, sodium acetate and the like.

Preferable examples of the suspending agent include surfactants such as stearyltriethanolamine, sodium lauryl sulfate, laurylaminopropionic acid, lecithin, benzalkonium chloride, benzethonium chloride, and glycerin monostearate; for example, polyvinyl alcohol. , Polybutylpyrrolidone, sodium oxymethylcellulose sodium, methylcellulose, hydroxymethylcellulose Hydrophilic polymers such as cellulose, hydroxyethylcellulose and hydroxypropylcellulose; polysorbates, polyoxyethylene hydrogenated castor oil, and the like.

 Preferred examples of the tonicity agent include sodium chloride, glycerin, D-mannitol, D-sorbitol, glucose and the like.

 Preferable examples of the buffer include buffers such as phosphate, acetate, carbonate, citrate and the like. '

 Preferable examples of the soothing agent include benzyl alcohol and the like.

 Preferable examples of the preservative include, for example, paraoxybenzoic acid esters, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, sorbic acid and the like.

 Preferred examples of the antioxidant include, for example, sulfite, ascorbate and the like.

 Preferable examples of the coloring agent include, for example, water-soluble edible tar dyes (eg, edible dyes such as edible red Nos. 2 and 3, edible yellows 4 and 5, edible blue Nos. 1 and 2, water-insoluble lakes). Dyes (eg, aluminum salts of the water-soluble edible tar dyes, etc.), and natural dyes (eg, β-potency rotin, chlorophyll, bengalara, etc.), etc.

Preferable examples of the sweetener include saccharin sodium, dipotassium glycyrrhizinate, aspartame, stevia and the like. Examples of the dosage form of the pharmaceutical composition include tablets (including sublingual tablets and orally disintegrating tablets), capsules (including soft capsules and microcapsules), granules, powders, troches, syrups, emulsions, Oral preparations such as suspensions; and injections (eg, subcutaneous injections, intravenous injections, intramuscular injections, intraperitoneal injections, etc.), external preparations (eg, intranasal preparations, transdermal preparations, Ointments, etc.), suppositories (eg, rectal suppositories, vaginal suppositories, etc.), parenteral preparations such as pellets, drops, eye drops, pulmonary preparations (inhalants), etc. Alternatively, it can be safely administered parenterally. In addition, these preparations may be controlled-release preparations such as immediate-release preparations and sustained-release preparations (eg, sustained-release micro force cells).

 The pharmaceutical composition can be produced by a method commonly used in the technical field of formulation, for example, the method described in the Japanese Pharmacopoeia. Hereinafter, the specific production method of the drug product will be described in detail.

 For example, in the case of oral preparations, active ingredients include, for example, excipients (eg, lactose, sucrose, starch, D-mannitol!), Disintegrants (eg, carboxymethylcellulose sodium), binders (eg, For example, add starch arsenide, gum arabic, lipoxymethylcellulose, hydroxypropylcellulose, polyvinylpyrrolidone, etc. or lubricant (eg, talc, magnesium stearate, polyethylene glycol 600, etc.) Then, if necessary, it is produced by coating with a coating base in a manner known per se for the purpose of taste masking, enteric coating or persistence.

 Examples of the coating base include a sugar coating base, a water-soluble film coating base, an enteric film coating base, a sustained release film coating base, and the like.

 As a sugar-coating base, sucrose is used, and one or more kinds selected from talc, precipitated calcium carbonate, gelatin, gum arabic, pullulan, carnauba wax and the like may be used in combination.

 Examples of the water-soluble film coating base include cellulosic polymers such as hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, and methylhydroxyethylcellulose; polyvinyl acetal acetylaminoacetate; And synthetic polymers such as aminoalkyl methacrylate copolymer E (Eudragit E (trade name), Rohm Pharma Co., Ltd.) and polyvinylpyrrolidone; and polysaccharides such as pullulan.

Enteric film coating bases include, for example, hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate succinate, carboxymethylethylcellulose, and acetic acid phthalate. Cellulose-based polymers such as llulose; methacrylic acid copolymer L (Eidragit L (trade name), Rohm Pharma Co., Ltd.), methacrylic acid copolymer LD (Eudragit L-1 30 D55 (trade name), Kuchiichi Mufarma Co., Ltd.) And methacrylic acid copolymers S (Eudragit S (trade name), Rohm Pharma Co., Ltd.); and acrylic acid-based polymers; natural products such as shellac.

 Examples of the sustained-release film coating base include cellulosic polymers such as ethyl cellulose; aminoalkyl methacrylate copolymer RS (Oidragit RS (trade name), Rohm Pharma Co., Ltd.), and ethyl acrylate * methyl acrylic Acrynolate-based polymers such as acid-methyl copolymer suspension [Eudragit NE (trade name), Kuchiichi Mufalma Co., Ltd.] and the like.

 The above-mentioned coating bases may be used as a mixture of two or more kinds at an appropriate ratio. Further, at the time of coating, a light-shielding agent such as titanium oxide, iron sesquioxide and the like may be used.

Injectables contain active ingredients as dispersants (eg, polysorbate 80, polyoxyethylene hydrogenated castor oil 60, etc.), polyethylene glycol, carboxymethyl cellulose, sodium alginate, etc., preservatives (eg, methylparaben, propylparaben, benzyl alcohol) , Chlorobutanol, phenol, etc.), isotonic agents (eg, sodium chloride, glycerin, D_mannitol, D-sorbitol, dextrose, etc.) and aqueous solvents (eg, distilled water, physiological saline, Ringer's solution, etc.) It is manufactured by dissolving, suspending or emulsifying in an oily solvent (eg, vegetable oil such as olive oil, sesame oil, cottonseed oil, corn oil, propylene glycol, etc.). At this time, if necessary, additives such as a solubilizing agent (eg, sodium salicylate, sodium acetate, etc.), a stabilizer (eg, human serum albumin, etc.), a soothing agent (eg, benzyl alcohol, etc.) may be used. . The compound of the present invention has a blood sugar lowering action, a blood lipid lowering action, a blood insulin lowering action, an insulin resistance improving action, an insulin sensitivity enhancing action, and a retinoid-related receptor function regulating activity. The function-modulating activity as used herein means both agonist activity and antagonist activity.

 In addition, retinoid-related receptors are DNA-binding transcription factors that are contained in nuclear receptors and have ligands for signal molecules such as fat-soluble vitamins. These are monomeric receptors and homodimeric receptors. It may be any of a body and a heterodimeric receptor.

 Here, as the monomer type receptor, for example, retinoid O receptor (hereinafter sometimes abbreviated as R〇R) a (GenBank Accession No. L14611), ROR jS (GenBank Accession No. L14160), ROR r Ev-erb (GenBank Accession No.M24898), R ev — erb β (GenBank Accession No. L31785); ERR a (GenBank Accession No. X51416), ERR jS (GenBank Accession No. X51417); Ftz-FI (GenBank Accession No. S65876); Ftz-FIβ (GenBank Accession No. M81385); TI x (GenBank Accession No. S77482); GCNF (GenBank Accession No. U14666). Can be

 Examples of homodimer-type receptors include retinoid X receptor (hereinafter sometimes abbreviated as RXR) a (GenBank Accession on No. X52773) RXR / 3 (GenBank Accession No. M84820), RXR r (GenBank Accession No. U38480); C OUP a (GenBank Accession No. X12795), COUP j3 (GenBank Accession No. M64497), COUP r (GenBank Accession No. X12794); TR2 o; (GenBank Accession No. M29960), TR2 3 (GenBank Accession No. L27586); or a homodimer formed by HNF4a (GenBank Accession No. X76930), HNF4r (GenBank Accession No. Z49826), or the like.

The heterodimeric receptor includes, for example, the above-mentioned retinoid X receptor (R XR o !, RXRj3 or RXR) and retinoid A receptor (hereinafter sometimes abbreviated as RAR) (GenBank Accession No. X06614). ), RARβ (GenBank Accession No. Y00291), RARa (GenBank Accession No. M24857); Thyroid hormone receptor (hereinafter sometimes abbreviated as TR) (GenBank Accession No. M24748) , TRj3 (GenBank Accession No. M26747); Vitamin D receptor (VDR) (GenBank Accession No. J03258); Peroxisome proliferator-responsive receptor (hereinafter sometimes abbreviated as P PAR) (GenBank Accession No. L02932), PPAR / 3 (PP AR δ) (GenBank Accession No. U10375), PP AR r (GenBank Accession No. L40904); LXR (GenBank Accession No. U22662), LXR, 8 (GenBank Accession No. U14534); FX (GenBank Accession No. U18374); MB 67 ( GenBank Accession No. L29263); ONR (GenBank Accession No. X75163); and NURa (GenBank Accession No. L13740), NUR] 3 (GenBank Accession No. X75918), NURr (GenBank Accession No. U12767) A heterodimer formed by one type of receptor is exemplified.

 The compounds of the present invention include, among the above-mentioned retinoid-related receptors, retinoid X receptors (RXRa, RXR / 3, RXRr) and peroxisome proliferator-activated receptors (PPARc¾, PPARi3 (PPARδ), PPARr). It has an excellent ligand activity against, and is useful as an agonist, a partial agonist (partial agonist), an antagonist or a partial antagonist (partial antagonist) for these receptors.

 Furthermore, the compound of the present invention is a heterodimeric receptor formed by a retinoid X receptor and a peroxisome proliferator-responsive receptor (eg, a heterodimeric receptor formed by RXRa and PPAR δ, RXRo ! And PPART have an excellent ligand activity for a peroxisome proliferator-activated receptor in a heterodimeric receptor, etc.).

 Therefore, the retinoid-related receptor ligand of the present invention is suitably used as a peroxisome proliferator-activated receptor ligand or a retinoid X receptor ligand.

 Further, the compound of the present invention is characterized by a peroxisome proliferator-activated receptor (PP)

Since it has excellent antagonistic activity against ARr), it does not have a weight gain effect. In addition, the compound of the present invention can exert a blood glucose lowering effect by suppressing the differentiation of preadipocytes into adipocytes and improving insulin resistance based on the PPARr antagonistic activity. The compound of the present invention is a prophylactic / therapeutic agent for diabetes (eg, type 1 diabetes, type 2 diabetes, gestational diabetes, etc.); hyperlipidemia (eg, hypertriglyceridemia, hypercholesterolemia, low HDL blood)・ Improvement of insulin resistance; Insulin sensitivity enhancer; Insufficiency of glucose tolerance [I GT (I immediately aired Glucose Tolerance)] Can be used as an inhibitor of the transition from glucose to diabetes.

 The Diabetes Society of Japan reported new criteria for diabetes in 1999.

 According to this report, diabetes is defined as a fasting blood glucose level (Dalcose concentration in venous plasma) of 126 mg Zd 1 or more, 75 g transglucose tolerance test (75 g OGTT), and a 2-hour value (glucose concentration in venous plasma). Is 200 mgZd 1 or more, and the blood glucose level (glucose concentration in venous plasma) at any time is 20 OmgZd 1 or more. In addition, those who do not fall under the above-mentioned diabetes and have a fasting blood glucose level (glucose concentration in venous plasma) of less than 11 OmgZd 1 or a 75 g transglucose tolerance test (75 gOGTT) 2 hour value (static ^ R plasma A state in which the glucose concentration is less than 140 mg / d1 ”(normal type) is not referred to as“ normal type ”.

 New criteria for diabetes were reported by the ADA (American Diabetes Association) in 1997 and by the WHO in 1998. According to these reports, diabetes is defined as a fasting blood glucose level (glucose concentration in venous plasma) of 126 mg / d1 or more, and a 2-hour glucose glucose load test (75 g glucose concentration in venous plasma). ) Is a state showing SO OmgZd l or more.

According to the above report, impaired glucose tolerance refers to a fasting blood glucose level (glucose concentration in venous plasma) of less than 126 mg Zd1 and a 2-hour value of 75 g translobulin glucose tolerance test (venous plasma Is less than 140 mg / d1 and less than 20 OmgZd1. In addition, the ADA reported that fasting blood glucose (Dalcos concentration in venous plasma) was ll Omg. / 状態 1 or more and less than 1 26 mg / d 1 is called IFG (Impaired Fasting Glucose). On the other hand, according to the report of WHO, among the IFG (Impaired Fasting Glucose), the condition that the 2-hour value (glucose concentration in venous plasma) of a 75 g transglucose tolerance test is less than 14 OmgZd 1 is defined as IFG (Unpaired Fasting Glucose). Fasting Giycemia).

 The compound of the present invention is also used as a prophylactic / therapeutic agent for diabetes, borderline type, impaired glucose tolerance, IFG (Immediate aired Fasting Glucose) and IFG (Impaired Fasting Giycemia) determined by the above-mentioned new criteria. Further, the compound of the present invention can also prevent the progression of diabetes from borderline type, impaired glucose tolerance, IFG (Impaired Fasting Glucose) or IFG (Impaired Fasting Giycemia).

 The compound of the present invention may be used, for example, for diabetic complications [eg, neuropathy, nephropathy, retinopathy, cataract, macrovascular disorder, osteopenia, diabetic hyperosmotic coma, infectious diseases (eg, respiratory infections, urine Tract infections, digestive organ infections, skin and soft tissue infections, lower limb infections, etc.), diabetic gangrene, xerostomia, decreased hearing, cerebrovascular disorders, peripheral blood circulation disorders, etc.), obesity, osteoporosis, cachexia (Eg, cancer cachexia, tuberculosis cachexia, diabetic cachexia, hematological cachexia, endocrine disease cachexia, cachexia due to infectious cachexia or cachexia due to late immune deficiency syndrome), fatty liver , Hypertension, polycystic ovary syndrome, renal disease (eg, diabetic nephropathy, glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive renal sclerosis, end-stage renal disease, etc.), muscular dystrophy, myocardium Infarction, angina, cerebrovascular disease ( , Cerebral infarction, stroke), insulin resistance syndrome, syndrome X, hyperinsulinemia, impaired perception in hyperinsulinemia, tumors (eg, leukemia, breast cancer, prostate cancer, skin cancer, etc.), irritable bowel syndrome , Acute or chronic diarrhea, inflammatory diseases (eg, Alzheimer's disease, rheumatoid arthritis, osteoarthritis, osteoarthritis, low back pain, gout, inflammation after surgical trauma, remission of swelling, neuralgia, pharyngolaryngitis , Cystitis, hepatitis (including non-alcoholic steatohepatitis), pneumonia, colitis, inflammatory bowel disease, ulcerative colitis, etc., and visceral obesity syndrome.

The compound of the present invention has a total cholesterol lowering effect and has a plasma anti-atherosclerosis index It can be used as a prophylactic and therapeutic agent for arteriosclerosis (eg, atherosclerosis, etc.) to increase [(HD L cholesterol Z total cholesterol) X 100].

 The compound of the present invention may also be used for improving symptoms such as abdominal pain, nausea, vomiting, and upper abdominal discomfort associated with peptic ulcer, acute or chronic gastritis, biliary dyskinesia, cholecystitis, etc. Can be.

 Furthermore, the compound of the present invention may be used as a therapeutic agent for slimming and phagocytosis (weight gain in subjects to which slimming or phagocytosis is administered) or a therapeutic agent for obesity, for example, to regulate (enhance or suppress) appetite. it can.

 The compound of the present invention has a TNF-α inhibitory effect (an effect of reducing the amount of TNF-α production in living tissues and an effect of reducing the activity of TNF-α), and prevents and treats inflammatory diseases in which TNF_Q! Is involved. Also used as medicine. Such inflammatory diseases include, for example, diabetic complications (eg, retinopathy, nephropathy, neuropathy, macrovascular disorders, etc.), rheumatoid arthritis, osteoarthritis, osteoarthritis, back pain, gout And inflammation after surgery and trauma, remission of swelling, neuralgia, pharyngolaryngitis, cystitis, hepatitis, pneumonia, gastric mucosal damage (including gastric mucosal damage caused by aspirin).

 The compound of the present invention has an inhibitory effect on apoptosis, and is also used as a preventive / therapeutic agent for diseases associated with promotion of apoptosis. Here, diseases associated with promotion of apoptosis include, for example, viral diseases (eg, AIDS, fulminant hepatitis, etc.), neurodegenerative diseases (eg, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Retinitis pigmentosa, cerebellar degeneration, etc., spinal dysplasia (eg, aplastic anemia, etc.), ischemic disease (eg, myocardial infarction, stroke, etc.), liver disease (eg, 7-leukor hepatitis, hepatitis B) , Hepatitis C, etc.), joint diseases (eg, osteoarthritis, etc.), atherosclerosis and the like.

The compound of the present invention reduces visceral fat, suppresses visceral fat accumulation, improves glucose metabolism, improves lipid metabolism, improves insulin resistance, suppresses oxidized LDL production, improves lipoprotein metabolism, improves coronary artery metabolism, and improves cardiovascular complications. Prevention and treatment, prevention and treatment of heart failure complications, reduction of blood remnant, prevention and treatment of anovulation, prevention and treatment of hirsutism, It is also used for prevention and treatment of blood disorders.

 The compound of the present invention is also used for secondary prevention of the above-mentioned various diseases (eg, cardiovascular events such as myocardial infarction). The dose of the compound of the present invention varies depending on the administration subject, administration route, target disease, symptoms, and the like.For example, when orally administered to an adult diabetic patient, the dose is usually about 0.005 to 5 Omg / kg as a single dose. The body weight is preferably 0.01 to 2 mg / kg body weight, more preferably 0.025 to 0.5 mg Zkg body weight, and it is desirable to administer this amount once to three times a day. The compound of the present invention is a therapeutic agent for diabetes, a therapeutic agent for diabetic complications, a therapeutic agent for hyperlipidemia, an antihypertensive agent, an antiobesity agent, a diuretic agent, a chemotherapeutic agent, an immunotherapeutic agent, an antithrombotic agent, and an improvement in cachexia. It can be used in combination with drugs such as drugs (hereinafter abbreviated as concomitant drugs). At this time, the timing of administration of the compound of the present invention and the concomitant drug is not limited, and they may be administered to the subject at the same time or at an interval.

 The concomitant drug may be a low molecular compound, a high molecular protein, a polypeptide, an antibody, or a vaccine. The dose of the concomitant drug can be appropriately selected based on the clinically used dose. The compounding ratio of the compound of the present invention and the concomitant drug can be appropriately selected depending on the administration subject, administration route, target disease, symptom, combination, and the like. For example, when the administration subject is a human, the concomitant drug may be used in an amount of 0.01 to 100 parts by weight based on 1 part by weight of the compound of the present invention.

The antidiabetic drugs include insulin preparations (eg, animal insulin preparations extracted from the stomach of the mouse and bush; human insulin preparations genetically synthesized using Escherichia coli and yeast; insulin zinc; protamine) Insulin zinc; insulin fragment or derivative (eg, INS-1 etc.), insulin resistance improver (eg, pioglitazone hydrochloride, troglitazone, oral ciglitazone or its maleate, GI-262570, JTT-501) , M Compounds described in CC—555, YM—440, KRP—297, CS—011, FK-614, WO 99/58510 (for example, (E) —4— [4— (5—Methyl-2-phenyl-4 1-oxazolylmethoxy) benzyloxyimino] —4-monophenylbutyric acid), NN—622, AZ—242, BMS—298 585, ON-ichi 5816, LM—4156, BM-13—1258, MB X — 102, GW-1536, etc.), hi-darcosidase inhibitors (eg, poglipoise, acarpoise, miglitol, emiglitate, etc.), biguanides (eg, phenformin, metformin, buformin, etc.), insulin secretagogue [sulfonylゥ Rare agents (eg, tolptamide, dalibenclamide, dali clazide, chlorpropamide, tolazamide, acethexamide, daliclopyramide, glimepiride, dalipizide, dalibzole, etc.), repaglinide, nate Linid, mitiglinide or its calcium salt hydrate, GLP-1 etc.), dipeptidyl peptidase IV inhibitor (eg, NVP-DPP-278, PT-100, NVP-DPP-728, LAF237, etc.), β3-agonist (Eg, CL-316243, SR-58611-A, UL-TG-307, SB-226552, AJ-9677, BMS-196085, AZ-40040, etc.), Amylinagonist (eg, pramlintide etc.), phosphotyrosine phosphata Inhibitors (eg, vanadic acid, etc.), gluconeogenesis inhibitors (eg, glycogen phosphorylase inhibitor, glucose-16-phosphatase inhibitor, glucagon antagonist, etc.), SGLUT (sodium-glucose cotransporter) inhibitor ( For example, T-1 1095).

Therapeutic agents for diabetic complications include aldose reductase inhibitors (eg, tolurestat, epalrestat, zenarestat, zovolrestat, minalrestat, fidalestat (SNK-860), CT-112, etc.), neurotrophic factors ( Eg, NGF, NT-3, BDNF, etc., neurotrophic factor production · secretion enhancer [eg, neurotrophin production · secretion enhancer described in W〇01 Z 14372 (eg, Phenyl) —2— (2-methyl-1-midazolyl) -15- (3- (2-methylphenoxy) propyl) oxazole, etc.), PKC inhibitors (eg, LY-333531, etc.), AGE inhibitors ( For example, ALT 946, pimagedin, pyratoxatin, N-phenacylthiazolidome promide (ALT 766), EXO-226, etc., active oxygen scavengers (eg, thioctic acid, etc.), cerebral vasodilators ( For example, tiapride, mexiletine, etc.).

 Examples of therapeutic agents for hyperlipidemia include HMG-CoA reductase inhibitors (eg, pravastatin, simvastatin, oral pastatin, atorvastatin, fluvastatin, ripantile, seripastatin, itavastatin, ZD-4 522 or their salts (eg, sodium salt, etc.), fibrate-based compounds (eg, bezafibrate, beclobrate, binifibrate, ciprofibrate, clinofibrate, clofibrate, clofibrate, etofibrate, ethofibrate, huetibrate) Nofibrate, gemfibrate gill, nicofibrate, pyrifibrate, ronifibrate, simfibrate, theofibrate, etc., squalene synthase inhibitors (eg, compounds described in W097Z1022, such as N) — [[(3R, 5S)-1_ (3-acetoxy-2, 2-dimethylpropyl) -7-chloro-5- (2,3-dimethoxyphenyl) -2-oxo-1,2,3,5-tetrahydro-4, tribenzoxazepin-3-yl ] Acetyl] piperidine-4-acetic acid, etc.), ACAT inhibitors (eg, Avasimibe), eflucimibe (Eucimibe), etc., anion exchange resins (eg, cholestyramine etc.), probucol, dicotinic acid Drug (eg, nicomol, niceritrol, etc.), ethyl icosapentate, plant sterol (eg, soysterol, gamma oryzanol, etc.) .

 Antihypertensive agents include angiotensin converting enzyme inhibitors (e.g., captopril, enalapril, delapril, etc.), angiotensin II antagonists (e.g., candesaltan cilexetil, oral sultan, eprosartan, valsantan, telmisartan, ilbesartan, and evening sosartan) ), Calcium antagonists (eg, manidipine, difludipine, dicardipine, amlodipine, efonidipine, etc.), potassium channel openers (eg, levocromakalim, L_27152, AL0671, NIP-121, etc.), clonidine, etc. .

Examples of anti-obesity agents include central anti-obesity agents (eg, dexfenfluramine, Fenfluramine, phentermine, sibutramine, ampuepramone, dexamphetamine, mazindol, phenylpropanolamine, clobenzolex, etc., lipase inhibitors (eg, orlistat, etc.), 33agonists (eg, CL—316243, SR— 58611-A, UL-TG-307, SB-226552, AJ-9677, BMS-196085, AZ-40140, etc., Peptide anorectics (eg, lebutin, CNTF (Ciliary neurotrophic factor), etc.) And cholecystokinin agonists (eg, lynch tribute, FPL-15849, etc.).

 Examples of diuretics include xanthine derivatives (eg, sodium theobromine salicylate, calcium theopromine salicylate, etc.), thiazide-based preparations (eg, ethiazide, cyclopentiazide, trichlormethiazide, hydrochlorothiazide, hydroflumethiazide, ventilhydrochloride) Oral thiazide, penflutide, polythiazide, methiclothiazide, etc.), anti-aldosterone preparations (eg, spironolactone, triamterene, etc.), carbonic anhydrase inhibitors (eg, acetazolamide, etc.), chlorobenzenesulfonamide preparations (eg, chlorthalidone, mefurside) , Indapamide and the like), azosemide, isosorbide, ethacrynic acid, pyrethrinide, bumetanide, furosemide and the like.

 Examples of chemotherapeutic agents include alkylating agents (eg, cyclophosphamide, ifosfamide, etc.), antimetabolites (eg, methotrexate, 5-fluoroperacil, etc.), anticancer antibiotics (eg, mitomycin, adriamycin) Etc.), plant-derived anti-cancer agents (eg, vincristine, vindesine, taxol, etc.), cis-bratin, carpoplatin, etopoxide and the like. Among them, a 5-fluorouracil derivative such as fluron or neoflururon is preferred.

Examples of immunotherapeutic agents include microbial or bacterial components (eg, muramyl dipeptide derivatives, picibanil, etc.), polysaccharides having immunopotentiating activity (eg, lentinan, schizophyllan, krestin, etc.), and gene engineering techniques. Obtained cytokins (eg, interferon, interleukin (IL), etc.), colony stimulating factors (eg, granulocyte colony stimulating factor, erythropoietin, etc.) Of these, interleukins such as IL-11, IL-2 and IL-12 are preferred.

 Examples of antithrombotic agents include heparin (eg, heparin sodium, heparin calcium, dalteparin sodium, etc.), perfurin (eg, perfurin potassium, etc.), antithrombin drugs (eg, argato Roban (aragatroban), etc., thrombolytic drugs (eg, perokinase (urokinase :), thisokinase (tisokinase), alteplase n (alteplase nateplase), monteplase (monteplase), pamitehu, fuse pamiteplase, etc.) Inhibitors (eg, ticlopidine hydrochloride (tic 1 op idi ne hydr och och 10 ri de), syrosazol, ethyl icosapentate, beraprost sodium (beraprost sodium), sarpogrelate hydrochloride (sarpogrelate hydr och 1) or ide) etc.).

 Examples of agents for improving cachexia include cyclooxygenase inhibitors (eg, indomethacin) [Cancer 1 Research (Cancer Research), Vol. 49, pp. 5935-5939, 1989], progesterone derivatives ( Examples: Megesterol acetate) [Journal of Clinical Oncology, Vol. 12, 2]: 3-225 pages, 1994], carbohydrate steroids (eg, dexamethasone, etc.), metoclobramide Drugs, tetrahydrocannabinol drugs (the literature is the same as above), fat metabolism improving agents (eg, eicosapentaenoic acid, etc.) [British Journal of Cancer, British Journal of Cancer, 68, pp. 314-318, 19993], growth hormone, IGF-1 or TNF-α, LIF, IL-16, which is a factor that induces cachexia. Antibodies to Oncoscintin M and the like.

Furthermore, concomitant drugs include nerve regeneration promoters (eg, Y-128, VX-855, prosaptide, etc.), antidepressants (eg, desipramine, amitriptyline, imipramine, etc.), antiepileptic drugs (eg, lamotrigine, etc.) , Antiarrhythmic drugs (eg, mexiletine, etc.), acetylcholine receptor ligands (eg, ABT-594, etc.), endoselin receptor antagonists (eg, ABT-627, etc.), monoamine uptake inhibitors (eg, Tramadol, etc.), narcotic analgesics (eg, morphine, etc.), GABA receptor agonists (eg, gearbapentin, etc.), << 2 receptor agonists (eg, clonidine, etc.), topical analgesics

(Eg, capsaicin, etc.), protein kinase C inhibitors (eg, LY-333531, etc.), anxiolytics (eg, benzodiazepine, etc.), phosphodiesterase inhibitors (eg, sildenafil (quenate), etc.), dopamine agonists (Eg, apomorphine, etc.), therapeutic agent for osteoporosis (eg, alfacalcidol, calcitriol, ercatonin, salmon calcitonin, estriol, ibriflavone, disodium pamidronate, sodium alendronate hydrate, disodium incadronate ), Anti-dementia drugs (eg, tacrine, donevezil, rivastigmine, galantamine, etc.), therapeutic agents for urinary incontinence and frequent urination (eg, flapoxant hydrochloride, oxyptinin hydrochloride, propiverine hydrochloride), etc., midazolam, ketoconazole And the like.

 The concomitant drug is preferably an insulin preparation, an insulin sensitizer, a dalcosidase inhibitor, a biguanide agent, an insulin secretagogue (preferably a sulfonyliderea agent) and the like.

 Two or more of the above concomitant drugs may be used in combination at an appropriate ratio. Preferred combinations when two or more concomitant drugs are used include, for example, the following.

 I) insulin sensitizers and insulin preparations;

2) insulin sensitizer and insulin secretagogue;

 3) an insulin sensitizer and an α-darcosidase inhibitor;

 4) insulin sensitizers and biguanides;

 5) insulin preparations and biguanides;

 6) insulin preparations and insulin secretagogues;

7) insulin preparations and α_darcosidase inhibitors;

 8) an insulin secretagogue and an α-darcosidase inhibitor;

 9) insulin secretagogues and biguanides;

 10) insulin sensitizer, insulin preparation and biguanide;

II) Insulin sensitizers, insulin preparations and insulin secretion promotion Agent;

 1 2) Insulin sensitizer, insulin preparation and α-darcosidase inhibitor;

13) Insulin sensitizers, insulin secretagogues and biguanides;

 14) Insulin sensitizer, insulin secretagogue and α-darcosidase inhibitor; and

 1 5) Insulin sensitizer, biguanide, a-darcosidase

When the compound of the present invention is used in combination with a concomitant drug, the amount of each drug can be reduced within a safe range considering the adverse effects of those drugs. In particular, the dose of the insulin sensitizer, insulin secretagogue and biguanide can be reduced from the usual dose. Therefore, the adverse effects that would be caused by these agents can be safely prevented. In addition, the dosage of diabetic complications, hyperlipidemia, and antihypertensives can be reduced, thus effectively preventing the adverse effects that would be caused by these agents. Hereinafter, the method for producing the compound of the present invention will be described.

 Compound (I) can be produced by a method known per se, for example, Method II to Method C shown below, or a method analogous thereto. In each of the following production methods, the raw material compound may be used as a salt. As such a salt, those exemplified as the salt of the compound (I) are used.

In the general formula (I), the compound (1-1) in which W is — W ′ —CH ₂ _ (W represents a bond or a divalent hydrocarbon residue having 1 or 19 carbon atoms) For example, it is manufactured by the following Method A.

Here, the “divalent hydrocarbon residue having 1 to 19 carbon atoms” represented by W ′ is the “divalent hydrocarbon residue having 1 to 20 carbon atoms” exemplified as W above. Among them, those having 1 to 19 carbon atoms can be mentioned. (Method A)

H-V-R (M l)

 [In the formula, z represents a leaving group, and other symbols have the same meanings as described above. ]

Examples of the leaving group represented by Z include a hydroxy group, a halogen atom, — 0 S 0 ₂ R ¹⁴ (R ¹⁴ is a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, an alkyl group having 1 to 4 carbon atoms) Represents an aryl group having 6 to 10 carbon atoms which may be substituted with an alkyl group, or an aralkyl group having 7 to 14 carbon atoms which may be substituted with an alkyl group having 1 to 4 carbon atoms. Can be

 Here, examples of the halogen atom include fluorine, chlorine, bromine and iodine.

R ^{1 4} represented by "alkyl group having 1 to 4 carbon atoms", "Ariru group alkylene Le carbon atoms which may be have 6-1 substituent in group 0 containing 1 to 4 carbon atoms" and "1 carbon atoms Examples of the alkyl group having 1 to 4 carbon atoms in the `` aralkyl group having 7 to 14 carbon atoms which may be substituted with an alkyl group of 4 '' include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec.-butyl. , T._butyl, and among them, methyl is preferable.

The Ariru group having a carbon number of 6 to 1 0 in the "Ariru group having a carbon number of 6 to 1 0 may be substituted with an alkyl group having a carbon number of 1-4" represented by R ^{1 4,} phenyl, naphthyl can be mentioned Of these, phenyl is preferred.

As the aralkyl group having 7 to 14 carbon atoms in the aralkyl group j having 7 to 14 carbon atoms which may be substituted with an alkyl group having 1 to 4 carbon atoms represented by R ¹⁴ , benzyl, phenethyl, naphthyl Methyl, especially Benzil Is preferred.

 In this method, compound (II) is reacted with compound (III) to produce compound (1-1).

 The amount of compound (II) to be used is preferably about 1 to about 3 molar equivalents relative to compound (II).

 When Z is a hydroxy group, this reaction is carried out by a method known per se, for example, the method described in Synthesis, page 1, (1981), or a method analogous thereto. That is, this reaction is usually performed in the presence of an organic phosphorus compound and an electrophile in a solvent that does not adversely influence the reaction.

 Examples of the organic phosphorus compound include triphenylphosphine, triptylphosphine, and the like.

 Examples of the electrophilic agent include getyl azodicarboxylate, diisopropyl azodicarboxylate, azodicarbonyldipiperidine and the like.

 The amount of the organophosphorus compound and the electrophile to be used is preferably about 1 to about 5 molar equivalents relative to compound (II).

 Solvents that do not adversely affect the reaction include, for example, ethers such as diethyl ether, tetrahydrofuran, and dioxane; halogenated hydrocarbons such as chloroform and dichloromethane; and aromatic hydrocarbons such as benzene, toluene, and xylene. Amides such as N, N-dimethylformamide; sulfoxides such as dimethyl sulfoxide. These solvents may be mixed and used at an appropriate ratio.

 The reaction temperature is usually about 150 to about 150 ° C, preferably about 110 to about 100 ° C.

 The reaction time is generally about 0.5 to about 20 hours.

When Z is a halogen atom or —OSO ₂ R ¹⁴ (R ¹⁴ is as defined above), this reaction is carried out according to a conventional method in the presence of a base in a solvent that does not adversely influence the reaction. Will be

Examples of the base include alkali metal salts such as potassium hydroxide, sodium hydroxide, sodium hydrogen carbonate and potassium carbonate; pyridine, triethylamine, Amines such as N, N-dimethylaniline and 1,8-diazabicyclo [5.4.0] pentacar 7-ene; metal hydrides such as potassium hydride and sodium hydride; sodium methoxide, sodium And alkali metal alkoxides such as ethoxide, potassium t.-butoxide.

 The amount of the base to be used is preferably about 1 to about 5 molar equivalents relative to compound (II).

 Solvents that do not adversely affect the reaction include, for example, aromatic hydrocarbons such as benzene, toluene, and xylene; ethers such as tetrahydrofuran, dioxane, and ethyl ether; ketones such as acetone and 2-butanone; Octogenated hydrocarbons such as dichloromethane; amides such as N, N-dimethylformamide; and sulfoxides such as dimethyl sulfoxide. These solvents may be mixed and used at an appropriate ratio. The reaction temperature is usually about 150 to about 150, preferably about -10 to about 100 ° C.

 The reaction time is usually about 0.5 to about 20 hours.

 The compound (1-1) thus obtained can be isolated and purified by known separation and purification means, for example, concentration, concentration under reduced pressure, solvent extraction, crystallization, recrystallization, phase transfer, chromatography and the like. it can. ,

Compound (II) used as a starting compound in the above-mentioned Method A can be produced according to a method known per se. For example, in the general formula (II), the compound (II-1) in which W ′ is a bond and Z is a hydroxy group can be produced by the method described in WO 01/38325 or the like, or a method analogous thereto. . Compound (III) can be produced according to a method known per se. In the general formula (I), V is a bond, W is —W ′ ′-CH = CH- (W ′ is a bond or a divalent hydrocarbon residue having 1 to 18 carbon atoms), and R ² is In the compound (1-2), which is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; and in the general formula (I), V is a bond, W is —W ′ ′ — CH ₂ — CH ₂ — (W ′ has the same meaning as described above), and the compound (1-3) in which R ² is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group is as follows: It is also manufactured by Method B.

 Here, the “divalent hydrocarbon residue having 1 to 18 carbon atoms” represented by W ′, represents the “divalent hydrocarbon residue having 1 to 20 carbon atoms” exemplified as W above. Among them, those having 1 to 18 carbon atoms are mentioned.

(Method B)

Process 1

R1-X-0-Y (I -2)

Process 2

[Wherein, R ² ′ represents an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, and other symbols have the same meanings as described above. ]

As "optionally substituted hydrocarbon group" and "optionally substituted heterocyclic group" represented by R ² ', it includes those exemplified for the aforementioned R ^2.

(Process 1)

 In this step, compound (1-2) is produced by reacting compound (IV) with a phosphonium salt.

The reaction between compound (IV) and the phosphonium salt is carried out in a conventional manner in the presence of a base in a solvent that does not adversely influence the reaction. Examples of the phosphonium salt include, for example, a compound represented by the formula: R ² 'C¾P (C ₆ H ₅ ) ₃ Za

[Wherein, R ² ′ has the same meaning as described above, and Za represents a halogen atom.]. Here, examples of the halogen atom represented by Za include chlorine, bromine, and iodine. The phosphonium salt can be produced according to a method known per se.

 The amount of the phosphonium salt to be used is generally about 1 to about 5 molar equivalents, preferably about 1 to about 3 molar equivalents, relative to compound (IV).

 Examples of the base include alkali metal salts such as sodium hydroxide, hydroxylated lime, carbonated lime, sodium carbonate and sodium hydrogen carbonate; amines such as pyridine, triethylamine, N, N, -dimethylaniline; hydrogenation Metal hydrides such as sodium and potassium hydride; and alkali metal alkoxides such as sodium ethoxide, sodium methoxide and potassium t-butoxide.

 The amount of the base to be used is preferably about 1 to about 5 mol equivalent relative to compound (IV).

 Solvents that do not adversely affect the reaction include, for example, aromatic hydrocarbons such as benzene, toluene, and xylene; ethers such as dioxane, tetrahydrofuran, and dimethoxetane; alcohols such as methanol, ethanol, and propanol; Amides such as dimethylformamide; sulfoxides such as dimethylsulfoxide; halogenated hydrocarbons such as chloroform, dichloromethane, 1,2-dichloroethane, 1,1,2,2-tetrachloroethane, and the like. Can be These solvents may be used in a mixture at an appropriate ratio.

 The reaction temperature is usually about 150 ° C to about 150 ° C, preferably about -10 ° C to about 100 ° C.

 The reaction time is, for example, about 0.5 to about 30 hours.

 The compound (I-2) thus obtained can be isolated and purified by known separation and purification means, for example, concentration, concentration under reduced pressure, solvent extraction, crystallization, recrystallization, phase transfer, chromatography and the like. it can.

The compound (1-2) was isolated without isolating the compound (1-2). As it is, it may be used as a raw material in the next step 2.

 (Process 2)

 In this step, compound (1-3) is produced by subjecting compound (1-2) to a reduction reaction.

 This reaction is carried out in a conventional manner under a hydrogen atmosphere or in the presence of a hydrogen source such as formic acid and a metal catalyst in a solvent that does not adversely influence the reaction.

 Examples of the metal catalyst include transition metal catalysts such as palladium-carbon, palladium black, platinum oxide, Raney nickel, Wilkinson catalyst and the like. The amount of the transition metal catalyst to be used is preferably about 0.01 to about 10 molar equivalents relative to compound (1-2).

 Solvents that do not adversely affect the reaction include, for example, aromatic hydrocarbons such as benzene, toluene, and xylene; ethers such as tetrahydrofuran, dioxane, and ethyl ether; halogenated hydrocarbons such as chloroform and dichloromethane; Amides such as N, N-dimethylformamide; alcohols such as methanol, ethanol and isopropanol. These solvents may be used in a mixture at an appropriate ratio.

 The reaction temperature is usually about -50 to about 150 ° C, preferably about 110 to about 100 ° C.

 The reaction time is usually about 0.5 to about 20 hours.

The compound (1-3) thus obtained can be isolated and purified by known separation and purification means, for example, concentration, concentration under reduced pressure, solvent extraction, crystallization, recrystallization, phase transfer, chromatography and the like. it can. In the general formula (I), V is a bond, W is - W ', -CH = CH- ( W' is as defined above), R ² gar ^{PO (OR 8) (OR 9} ) (R wherein ^s and R ⁹ are as defined above) (1-4); and in general formula (I), V is a bond, W is —W, '— CH ₂ —CH ₂ — (W' Is as defined above), and the compound (1-5) wherein R ² is —P〇 (OR ⁸ ) (OR ⁹ ) (R ⁸ and R ⁹ are as defined above) is It is also manufactured by the method. (Method C)

 R! -X-Q-Y- k (CHJ-~~ N B ^ -W '-CHO (IV)

Process 1

R X X-Q-Y ~ f A ^-(CH ΊJ '-n ~ B- † W-CH = CH-P0 (0R ⁸ ) (OR ⁹ ) (Table 4)

Process 2

Ri-XQY- ^ A ^ -CCH ^ B4W '-CH ■ R2 C "H' · 2 PO (OR 8) (OR 9) ( door 5)

[Wherein each symbol has the same meaning as described above. ]

 (Process 1)

 In this step, compound (1-4) is produced by reacting compound (IV) with an organic phosphorus reagent.

 This reaction is carried out according to a conventional method, in the presence of a base, in a solvent that does not adversely influence the reaction.

 Examples of the organic phosphorus reagent include tetramethyl methylenediphosphonate, tetraethyl methylenediphosphonate, and tetraisopropyl methylenediphosphonate.

 The amount of the organophosphorus reagent to be used is preferably about 1 to about 10 molar equivalents relative to compound (IV).

Examples of the base include alkali metal salts such as potassium hydroxide, sodium hydroxide, sodium hydrogen carbonate and potassium carbonate; pyridine, triethylamine, Amines such as N, N-dimethylaniline and 1,8-diazabicyclo [5.4.0] indene 7-ene; metal hydrides such as potassium hydride and sodium hydride; sodium methoxide, sodium Alkoxides such as ethoxide and potassium t.-butoxide.

 The amount of the base to be used is preferably about 1 to about 5 molar equivalents relative to compound (IV).

 Solvents that do not adversely affect the reaction include, for example, aromatic hydrocarbons such as benzene, toluene, and xylene; ethers such as tetrahydrofuran, dioxane, and ethyl ether; halogenation such as chloroform and dichloromethane. Hydrocarbons; amides such as N, N-dimethylformamide; and sulfoxides such as dimethyl sulfoxide. These solvents may be mixed and used at an appropriate ratio.

 The reaction temperature is usually about 150 to about 150 ° C, preferably about -10 to about 100 ° C.

 The reaction time is generally about 0.5 to about 20 hours.

 The compound (I-4) thus obtained can be isolated and purified by known separation and purification means, for example, concentration, concentration under reduced pressure, solvent extraction, crystallization, recrystallization, phase transfer, chromatography and the like. it can.

 Alternatively, without isolating compound (1-4), a reaction mixture containing compound (1-4) may be used as it is as a starting material in the next step 2.

 (Process 2)

 In this step, compound (1-5) is produced by subjecting compound (1-4) to a reduction reaction.

 This reaction is carried out, for example, in the same manner as in Step 2 of the above-mentioned Method B.

 The compound (1-5) thus obtained can be isolated and purified by known separation and purification means, for example, concentration, concentration under reduced pressure, solvent extraction, crystallization, recrystallization, phase transfer, chromatography and the like. it can.

Compound (IV) used as a starting compound in the above-mentioned Method B and Method C can be produced according to a method known per se. For example, in the general formula (IV), the compound (IV-1) in which W ′ is a bond can be produced by the method described in WO 01/38325 or a method analogous thereto.

 Further, the compound (IV-2) in which W ′ ′ is a divalent hydrocarbon residue having 1 to 18 carbon atoms in the general formula (IV) may be produced, for example, according to the following Method D. Can be.

 (Method D)

R 1-XQY (CH _{2) "B • W '- CH 2 0H} (V - 1)

R 1-XQY A-(CH ₂ ) '-CHO (IV-2)

 [Wherein each symbol has the same meaning as described above. ]

 In this method, compound (IV-2) is produced by subjecting compound (V-1) to an oxidation reaction.

 This reaction is carried out according to a conventional method in the presence of an oxidizing agent in a solvent that does not adversely influence the reaction.

 Examples of the oxidizing agent include metal oxidizing agents such as manganese dioxide, pyridinium chromate, pyridinium dichromate, and ruthenium oxide.

 The amount of the oxidizing agent to be used is preferably about 1 to about 10 molar equivalents relative to compound (V-1).

Solvents that do not adversely affect the reaction include, for example, aromatic hydrocarbons such as benzene, toluene, and xylene; ethers such as tetrahydrofuran, dioxane, and ethyl ether; halogenated hydrocarbons such as chloroform and dichloromethane. Is mentioned. These solvents may be used in a mixture at an appropriate ratio. The reaction temperature is usually about 150 to about 150 ° C, preferably about -10 to about 100 ° C.

 The reaction time is generally about 0.5 to about 20 hours. .

 Compound (IV-2) can be prepared by adding sulfur trioxide pyridine complex or compound (V-1) to compound (V-1) in a mixed solvent of halogenated hydrocarbons such as chloroform and dichloromethane and dimethyl sulfoxide, or in dimethyl sulfoxide. It can also be produced by reacting a reaction reagent such as oxalyl chloride and an organic base such as triethylamine and N-methylmorpholine.

 The amount of the reaction reagent to be used is preferably about 1 to about 10 molar equivalents relative to compound (V-1).

 The amount of the organic base to be used is preferably about 1 to about 10 molar equivalents relative to compound (V-1).

 The reaction temperature is usually from about 150 to about 150 ° (preferably, from about 110 to about 100 ° C.

 The reaction time is generally about 0.5 to about 20 hours.

 The compound (IV-2) thus obtained can be isolated and purified by a known separation and purification means, for example, concentration, concentration under reduced pressure, solvent extraction, crystallization, recrystallization, phase transfer, chromatography and the like.

Compound (V-1) used as a starting compound in the above-mentioned Method D can be produced according to a method known per se. For example, compound (V-1) in which W ′ ′ is a bond can be produced by the method described in W〇01 / 383325 or a method analogous thereto. Among the compounds used as starting materials (II) in the Method A, compounds wherein Z is a hydro alkoxy group (I I-2), and Z is a halogen atom or - OS_〇 ₂ ¹ ^ ⁴ (R 1 ⁴ is Compound (Π-3) having the same meaning as described above can be produced, for example, according to the following Method E.

(Method E) R ¹ -XQY— f A- (CH ₂ ) _n —:

工程 1

Process 1

R1-XQY— f A ^-(CHJ _n — N — / Ri5

Process 2

Ri-XQY— (A- (CH ₂ ) _n NB ^ — W'-CH, 0H (11-2)

Process 3

R1-XQY— (A-)-(CH ₂ ) — N B-^ — W'-CH ₂ Z '(|| -3)

Wherein, Z 'is a halogen atom or a OS0 ₂ R ¹⁴ (R ¹⁴ is as defined above), and other symbols are as defined above. ]

 (Process 1)

 In this step, compound (VI) is reacted with compound (VII) to produce compound (VIII).

 This reaction is carried out, for example, in the same manner as in the above-mentioned Method A.

 The compound (VIII) thus obtained can be isolated and purified by known separation and purification means, for example, concentration, concentration under reduced pressure, solvent extraction, crystallization, recrystallization, phase transfer, chromatography and the like.

 Further, the reaction mixture containing the compound (VIII) may be used as it is as a raw material in the next step 2 without isolating the compound (νιπ).

Compound (VI) and compound (VII) can be produced according to a method known per se. Compound (VI) can be produced, for example, by the method described in EP-A 710659, EP-A 629624 (Japanese Patent Application Laid-Open No. 7-53555), WO 98/03505, or a method analogous thereto.

 Compound (VII) is described, for example, in Journal of Heterocyclic Chemistry, Vol. 24, p. 1669 (1987); Journal of Organic Chemistry, Vol. 62, 2649 Page (1997); Bioorganic & Medicinal Chemistry Letters, Vol. 6, p. 1047 (1996), or a method analogous thereto. .

 (Process 2)

 In this step, compound (VIII) is subjected to a reduction reaction to produce compound (II-2).

 This reaction is carried out according to a conventional method, in the presence of a reducing agent, in a solvent that does not adversely influence the reaction.

 Examples of the reducing agent include sodium borohydride, lithium borohydride, lithium aluminum hydride, diisobutylaluminum hydride and the like.

 The amount of the reducing agent to be used is preferably about 0.5 to about 10 molar equivalents relative to compound (VIII).

 Examples of solvents that do not adversely affect the reaction include aromatic hydrocarbons such as benzene, toluene, and xylene; halogenated hydrocarbons such as chloroform and dichloromethane; and hydrocarbons such as tetrahydrofuran, dioxane, and getyl ether. Ters; alcohols such as water, methanol, ethanol, and isopropanol; These solvents may be used in a mixture at an appropriate ratio.

 The reaction temperature is usually about 150 to about 150 ° C, preferably about -10 to about 100.

The reaction time is usually about 0.5 to about 20 hours. The compound (II-12) thus obtained can be isolated and purified by known separation and purification means, for example, concentration, concentration under reduced pressure, solvent extraction, crystallization, recrystallization, phase transfer, chromatography and the like. it can.

 Further, the reaction mixture containing the compound (II-12) may be used as it is as a raw material in the next step 3 without isolating the compound (II-12).

 (Process 3)

 In this step, compound (II-13) is produced by reacting compound (II-12) with a halogenating agent or a sulfonylating agent.

 As the halogenating agent, for example, hydrochloric acid, thionyl chloride, phosphorus tribromide or the like is used. In this case, a compound (III-3) in which Z ′ is a halogen atom (eg, chlorine or bromine) is obtained.

 The amount of the halogenating agent to be used is generally about 1-about 10 mol equivalent relative to compound (II-2).

 This reaction is carried out in a solvent such as aromatic hydrocarbons such as benzene, toluene and xylene; halogenated hydrocarbons such as dichloromethane and chloroform; ethers such as tetrahydrofuran, dioxane and getyl ether. The reaction is performed at 20 to about 100 ° C. for about 0.5 to about 24 hours. Further, an excess of a halogenating agent may be used as a solvent.

The sulfonylating agent, for example, methanesulfonyl chloride, chloride benzenesulfonic Ruhoniru, p- toluenesulfonyl chloride and the like are used, in this case, Z 'gar OS0 ₂ R ¹⁴ (R ¹⁴ is as defined above) (for example, methanesulfonate Compound (II-3) is obtained, which is dioxy, P-toluenesulfonyl chloride). The amount of the sulfonylating agent to be used is generally about 1 to about 10 molar equivalents relative to compound (Π-2).

In this reaction, for example, aromatic hydrocarbons such as benzene, toluene, and xylene; octacyclic hydrocarbons such as dichloromethane and chloroform; ethers such as tetrahydrofuran, dioxane, and getyl ether; The reaction is carried out in a solvent such as esters in the presence of a base at about 120 to about 100 ° C. for about 0.5 to about 24 hours. Examples of the base include amines such as triethylamine and N-methylmorpholine; metal salts such as sodium bicarbonate, potassium bicarbonate, sodium carbonate, and potassium carbonate.

 The amount of the base to be used is generally about 1 to about 10 molar equivalents relative to compound (II-2).

 The compound (II-3) thus obtained can be isolated and purified by known separation and purification means, for example, concentration, concentration under reduced pressure, solvent extraction, crystallization, recrystallization, phase transfer, chromatography and the like. . In each of the above-mentioned reactions, when the raw material compound has an amino group, a carboxyl group, a hydroxyl group, or a hydroxyl group as a substituent, a protecting group generally used in peptide chemistry or the like is introduced into these groups. The target compound can be obtained by removing the protecting group as needed after the reaction.

The protecting group of the Amino group include those exemplified for the aforementioned R ^5. Examples of the protecting group for the carbonyl group include C ₆ alkyl (eg, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, etc.), C ₇ _ ^ aralkyl (eg, benzyl, etc.), phenyl, trityl, silyl (e.g., trimethylsilyl, triethylsilyl, dimethyl-phenylalanine silyl, tert - butyldimethylsilyl, tert - butyl Jefferies chill silyl, etc.), C ₂ one ₆ an alkenyl (e.g., 1-Ariru) and the like. These groups may be substituted with one to three halogen atoms (eg, fluorine, chlorine, bromine, iodine, etc.), ₆ -alkoxy (eg, methoxy, ethoxy, propoxy, etc.) or nitro.

Examples of the hydroxyl-protecting group include those exemplified as the aforementioned R ⁴ . The protecting group of Karuponiru group, for example, cyclic Asetaru (e.g., 1, 3-Jiokisan), acyclic Asetaru (eg, etc. di C i _ ₆ alkyl § Se tar), and the like.

In addition, these protective groups can be removed by a method known per se, for example, Protective Groups in Organic Synthesis. in Organic Synthes is), published by John Wiley and Sons (1980). For example, acids, bases, ultraviolet light, hydrazine, phenylhydrazine, sodium N-methyldithiolrubamate, tetrabutylammonium fluoride, palladium acetate, trialkylsilyl halides (eg, trimethylsilyl chloride, trimethylsilylpromide) Etc.), a reduction method, etc. are used. When compound (I) contains optical isomers, stereoisomers, positional isomers, and rotamers, these are also contained as compound (I) and are synthesized by known synthesis methods and separation methods. Each can be obtained as a single item. For example, when the compound (I) has an optical isomer, the optical isomer resolved from the compound is also included in the compound (I).

 The optical isomer can be produced by a method known per se. Specifically, an optical isomer is obtained by using an optically active synthetic intermediate or by optically resolving the racemic final product according to a conventional method.

 As the optical resolution method, a method known per se, for example, a fractional recrystallization method, a chiral column method, a diastereomer method and the like are used.

 1) Fractional recrystallization method

 Racemic and optically active compounds (eg, (+) monomandelic acid, (_) monomandelic acid, (+)-tartaric acid, (-1) monotartaric acid, (+) — 1-phenethylamine, (-1)- 1-phenethylamine, cinchonine, (1) cinchonidine, brucine, etc.) to form a salt, which is separated by fractional recrystallization, and if necessary, a neutralization step to obtain a free optical isomer Method.

 2) Chiral column method

A method in which a racemate or a salt thereof is applied to a chiral column for separation of optical isomers. For example, in the case of liquid chromatography, a mixture of optical isomers is added to a chiral column such as E NAN TIO-〇 VM (] Soichi Co., Ltd. or Daicel CHI RAL series, and water, various buffer solutions (eg, Acid buffer), organic solvents (eg, ethanol, methanol, isopropanol, Acetonitrile, trifluoroacetic acid, getylamine, etc.) are developed alone or as a mixture to separate optical isomers. In the case of gas chromatography, for example, separation is performed using a chiral column such as CP-Chirasil-DeX CB (manufactured by GL Sciences).

 3) diastereomer method

 A racemic mixture is formed into a mixture of diastereomers by a chemical reaction with an optically active reagent, which is converted into a single substance through ordinary separation means (eg, fractional recrystallization, chromatographic method, etc.), and then subjected to hydrolysis. A method of obtaining an optical isomer by separating an optically active reagent site by a chemical treatment such as a reaction. For example, when compound (I) has hydroxy or 1,2-amino in the molecule, the compound and an optically active organic acid (for example, MTPA [0; -methoxy-α- (trifluoromethyl) phenylacetic acid]), (1) -menthoxyacetic acid, etc.) to give a diastereomer of an ester form or an amide form, respectively. On the other hand, when the compound (I) has a carboxylic acid group, the compound and an optically active amine or an alcohol reagent are subjected to a condensation reaction to obtain an amide or ester diastereomer, respectively. The separated diastereomer is converted into an optical isomer of the original compound by subjecting it to acid hydrolysis or basic hydrolysis reaction. Hereinafter, the present invention will be described in more detail with reference to Test Examples, Reference Examples, Examples, and Formulation Examples, but the present invention is not limited thereto.

 In the following Reference Examples and Examples,% indicates percent by weight unless otherwise specified. The room temperature indicates a temperature of 1 to 30 ° C.

 In the test examples, compound A is 5- [4- [2- (5-methyl-2-phenyl-1-4-oxazolyl) ethoxy] benzyl] -2,4-monothiazolidinedione, and [¾] —compound A is Compound A labeled with ¾ is shown. The compound A is a compound that binds to P PART and activates P PARTer.

 The sequence numbers in the sequence listing in the present specification indicate the following sequences.

[SEQ ID NO: 1] 3 shows the nucleotide sequence of primer XRA-U used in Reference Example 1a.

 [SEQ ID NO: 2]

The base sequence of the primer XRA-L used in Reference Example la is shown.

 [SEQ ID NO: 3]

7 shows the base sequence of PPRE-U used in Reference Example 2a.

 [SEQ ID NO: 4]

7 shows the nucleotide sequence of P PRE-L used in Reference Example 2a.

 [SEQ ID NO: 5]

3 shows the nucleotide sequence of primer TK-U used in Reference Example 2a.

 [SEQ ID NO: 6]

13 shows the nucleotide sequence of primer TK-L used in Reference Example 2a.

 [SEQ ID NO: 7]

3 shows the nucleotide sequence of primer PAG-U used in Reference Example 3a.

 [SEQ ID NO: 8]

3 shows the nucleotide sequence of primer PAG-L used in Reference Example 3a. Example

Test Example 1 Human 1 binding activity measurement

 Cell extract containing 1.5 wg / ml full-length hPPARTl prepared in Reference Example 1, 20 nM [¾] —Compound A (16Ci / dustol) (Amersham Pharmacia) and test compound in TEGM buffer at 4 for 16 hours Reacted. Activated carbon (Sigma) coated with 1401 dextran (Amersham Pharmacia) and gelatin (Sigma) was added to the reaction solution, left at 4 ° C. for 10 minutes, and then centrifuged at 910 × g for 10 minutes. After centrifugation, the radioactivity of 301 supernatants was measured by Topcount (Packard).

The binding inhibitory activity of the test compound was calculated as a percentage, with the measured value of addition of only 20 nM [] -Compound A being 100%, and the measurement value of simultaneous addition of 20 nM [¾] Compound A and ίΟΟ ^ Μ Compound A being 0%. did. Furthermore, the compound concentration and percentage value were analyzed using PRISM3.0 (Graphpad) to determine the IC ₅ of the test compound. Values were calculated. The results are shown in [Table 1]. [Table 1] Test compound I c ₅₀

 (Example number)

 1 0.034

 Thus, the compounds of the present invention have excellent PPARa binding activity.

Test Example 1 Evaluation of Compounds by Human PPARA

The cells transfected in Reference Example 2 were collected, suspended in a DMEM medium (Nikken Biomedical Research Institute) containing 0.1% BSA (containing no fatty acid) (Wako Pure Chemical Industries), and then placed in a 96-well white plate (C 8.8xl0 ³ cells were seeded at 601 in each well of Ichining Co., Ltd.). Subsequently, to each well, test compound 201 and compound A at final concentration {η}

Was added 20 ^ 1 (used as a stimulant), they were cultured for 48 hours in 5% C0 ₂ under 37 ° C. After removing the culture medium from a 96-well white plate (Koning), add 40 xl of Pitka Gene LT7.5 (Wako Pure Chemical), stir, and mix with 1420 ARVO Multi label Counter.

(Wallac) was used to measure luciferase activity.

10 Calculate the percentage of luciferase activity of Compound A as 100% and the luciferase activity without Compound A as 0%, and calculate the compound concentration and the percentage value using PRISM3.0 (Graph Pad). Analyze the IC _{5 of the} test compound. Values were calculated. The results are shown in [Table 2].

2] Test compound I c ₅₀

 (Example number)

 1 0.15

 Thus, the compounds of the present invention have excellent PPARr-RXRa hetero: body antagonist activity. Reference example la (cloning of the human RXR gene)

Cloning of the human RXR gene was performed using kidney cDNA (manufactured by Toyobo, trade name QUICK-Clone cDNA) as type III, reported by Mangelsdorf, DJ, et al. (Nature, 1990, 1991, 345 (6272), 224-2) A set of primers created based on the base sequence of the RXR gene

XRA-U: 5'-TTA GAA TTC GAC ATG GAC ACC AAA CAT TTC CTG-3 '(SEQ ID NO: 1)

 XRA-L: 5'-CCC CTC GAG CTA AGT CAT TTG GTG CGG CGC CTC-3 '(SEQ ID NO: 2)

Was performed by the PCR method using

 The PCR reaction was performed by the Hot Start method using AmpliWax PCR Gem 100 (Takara Shuzo). First, 1 O XLA PCR Buffer 2 \, 2.5 mM d NTP solution 3 (i l 2. M each of 2.5 M primer solution and 10 l of sterile distilled water were mixed to form a lower layer mixture. 1 jul of human kidney cDNA (1 ng / ml) as type 铸, 1 O XLA PCR Buffer 32.5 mM (1 ^^ cho? Solution 1, TaKaRa LA Taq DNA polymerase (Takara Shuzo) 0.5 K 24.5 ill of sterile distilled water was mixed to obtain an upper layer mixed solution.

 One Ampli Wax PCR Gem 100 (manufactured by Takara Shuzo) was added to the lower mixture, and the mixture was treated at 70 for 5 minutes and on ice for 5 minutes. The upper mixture was added to prepare a PCR reaction solution. The tube containing the reaction solution was set on a thermocycler (Perkin Elmer, USA) and treated at 95 ° C for 2 minutes. Further, a cycle of 15 seconds at 95 ° C. and 2 minutes at 68 ° C. was repeated 35 times, followed by treatment with 72 for 8 minutes.

 The obtained PCR product was subjected to agarose gel (1%) electrophoresis, and a 1.4 kb DNA fragment containing the RXRα gene was recovered from the gel, which was then transferred to pT7Blue-T vector (Takara Shuzo). As a result, a plasmid pTBT-hRXR was obtained. Reference Example 2a (Preparation of reporter plasmid)

 A DNA fragment containing the PPAR-responsive element (PPRE) of acetyl-CoA oxidase was prepared using the following 5'-terminal phosphorylated synthetic DNA.

PPRE-U: 5'-pTCGACAGGGGACCAGGACAAAGGTCACGTTCGGGAG-3 '(SEQ ID NO: 3) PPRE-L: 5'-pTCGACTCCCGAACGTGACCTTTGTCCTGGTCCCCTG-3 '(SEQ ID NO: 4) First, PPRE-U and P PRE-L were annealed, and then inserted into the Sail site of plasmid pBlueScript SK +. By determining the nucleotide sequence of the inserted fragment, a plasmid p BSS-P PRE 4 in which four PREs were linked in tandem was selected.

 Cloning of the HS V thymidine 'kinase' minimum 'promoter (TK promoter-1) region is based on the pRL-ΤK vector [Promega, USA], type Rutko. Promoter region of the thymidine kinase gene reported by Biuck (Luckow, B) et al. [Nucleic Acids Res. 1987, 15 (13), 5490] Primer set prepared with reference to the nucleotide sequence of

 TK-U: 5'-CCCAGATCTCCCCAGCGTCTTGTCATTG-3 '(SEQ ID NO: 5)

T-L: 5'-TCACCATGGTCAAGCTTTTAAGCGGGTC-3 '(SEQ ID NO: 6)

Was performed by the PCR method using

 The PCR reaction was performed by the Hot Start method using pliWax PCR Gem 100 (Takara Shuzo). First, 2.5X each of 10XLA PCR Buffer 2 2.5 mM dNTP solution 3 12.5 M primer solution and 10 μ 、 of sterile distilled water were mixed to form a lower layer mixed solution. In addition, 1 xl, 10 XL A PCR Buffer 3 fi 2.5 mM dNTP solution l 1, TaKaRa LA Taq DNA olymerase (Takara Shuzo) 0.5 UL 24.5 ιι \ of sterile distilled water was mixed to obtain an upper layer mixed solution. One Ampli Wax PCR Gem 100 (manufactured by Takara Shuzo) was added to the above lower mixture, and the mixture was treated at 70 ° C for 5 minutes and on ice for 5 minutes, and the upper mixture was added to prepare a PCR reaction solution. The tube containing the reaction solution was set in a thermal cycler (PerkinElmer, USA) and treated at 95 ° C for 2 minutes. Further, a cycle of 95 ° C. for 15 seconds and 68 ° C. for 2 minutes was repeated 35 times, followed by treatment at 72 ° C. for 8 minutes.

The obtained PCR product was subjected to agarose gel (1%) electrophoresis, After the 140 b DNA fragment containing the DNA fragment was recovered from the gel, it was introduced into pT7 Blue-T vector (Takara Shuzo). The fragment containing the TK promoter obtained by digesting this plasmid with the restriction enzymes Bglll and Ncol was ligated to the Bglll-Ncol fragment of the plasmid pGL3-Basic vector [Promega, USA] to form the plasmid P. GL3-TK was prepared.

 Plasmid pGL3-4ERPP-TK was prepared by ligating the obtained 4.9 kb Nhel-Xhol fragment of plasmid PGL3-TK with the Nhel-Xhol fragment 200b of plasmid pBSS-PPRE4.

 This plasmid GL3-4ERPP-TK was digested with BamHI (Takara Shuzo) and blunt-ended by treatment with T4 DNA polymerase (Takara Shuzo) to obtain a DNA fragment.

 On the other hand, pGFP-C1 (manufactured by Toyobo) was digested with Bsu36I (NEB), and then blunt-ended by treatment with T4 DNA polymerase (manufactured by Takara Shuzo) to obtain a 1.6 kb DNA fragment.

 By linking both DNA fragments, the reporter plasmid pGL3-4

ERPP-TK neo was constructed.

Reference Example 3a (cloning of human PPARa gene)

 The human PPARa gene was cloned using a heart cDNA (manufactured by Toyobo, trade name: QUICK-Clone cDNA) as type III, reported by Greene et al. [Gene Expr.;, 1995, 4 (4-5) Volume, 281

-P.299] primer set prepared with reference to the base sequence of the PPARr gene

 PAG-U: 5'-GTG GGT ACC GAA ATG ACC ATG GTT GAC ACA GAG-3 '(SEQ ID NO: 7)

PAG-L: 5'-GGG GTC GAC CAG GAC TCT CTG CTA GTA C GTC-3 '(SEQ ID NO:

8) Performed by the PCR method using-.

The PCR reaction was performed by the Hot Start method using AmpliWax PCR Gera 100 (Takara Shuzo). First, 10XLA PCR Buffer 21 A 2.5 mM dNTP solution 31 and a 1.5 M primer solution 2.51 each and sterile distilled water 10 μΛ were mixed to form a lower layer mixed solution. In addition, human heart cDNA (1 ng / ml) was used as type 1 in 11 and 10 XLA PGR Buffer 3 μΛ, 2.5 mM (1 ^ [cho? Solution 1 ^ 1, TaKaRa LA Taq DNA polymerase (Takara Shuzo) 0.5 24.5 ill of sterile distilled water was mixed to obtain an upper layer mixed solution.

 One AmpliWax PCR Gem 100 (Takara Shuzo) was added to the lower mixture, and the mixture was treated at 70 ° C for 5 minutes and on ice for 5 minutes. The upper mixture was added to prepare a PCR reaction solution. The tube containing the reaction solution was set on a thermal cycler (Perkin Elmer, USA) and treated at 95 ° C for 2 minutes. Further, a cycle of 15 seconds at 95 ° C and 2 minutes at 68 was repeated 35 times, followed by treatment at 72 ° C for 8 minutes.

 The obtained PCR product was subjected to agarose gel (1%) electrophoresis, and a 1.4 kb DNA fragment containing the PPARa gene was recovered from the gel, and inserted into pT7Blue-T vector (Takara Shuzo). The plasmid pTBT-hPPARr was obtained. Reference Example 1 Preparation of human PPARTI protein using C0S-1 cells

^Six 5xl0 COS-1 cells were seeded in a 150cm ² tissue culture flask (Koning), and cultured at 37 ° C under 5% CO ₂ for 24 hours. Transfection was performed using lipofectamine (GIBC0BRL). That is, the hPPARa expression plasmid (plasmid pTBT-hPPARa obtained in Reference Example 3a) of 125 I lipofectamine and 100 xl PLUS Reagent was mixed with opti-MEM (GIBC0 BRL) and transfected. A reaction mixture was prepared. 25 ml of the transfusion mixture was added to the CQS-1 cells, and the cells were cultured at 37 ° C. under 5% CO ₂ for 3 hours. Next, 25 ml of a DMEM medium (Nikken Institute of Biomedical Sciences) containing 10% FCS treated with activated carbon (Sigma) was added, and the cells were further cultured at 37 ° C. and 5% CO ₂ . Twenty-four hours later, the cells were replaced with 50 ml of MEM medium containing FCS treated with activated charcoal (Nikken Institute of Biomedical Research), and further cultured at 37 ° C. and 5% CO ₂ . After 48 hours, the transfected cells were collected and washed with TEG buffer (10 mM Tris-HCl (pH 7.2), 50 mM EDTA, 10% glycerol). Cells are 1 ml TEGM buffer (10 mM Tris-HCl (pH 7.2), 1 mM EDTA, 10% glycerol, 7 l / 100 ml jS-mercaptoethanol, 10 mM Na molybdate, 1 mM dithiothreitol, 2 tablets / lOOml Protease inhibitor Cocktail tablets (Boehringer Mannheim)) The cells were frozen in liquid nitrogen and thawed on ice for cell lysis. The extract was centrifuged at 228,000 xg at 4 ° C for 20 min to remove cell debris, and the supernatant was stored at -80 ° C until use.

Reference Example 2 Co-transfection of human PPARa, RXRo; expression plasmid and repo overnight plasmid into COS 1 cells

150 cm ² and tissue culture Flask (co twelve Ngusha) in COS- 1 cells 5Chi0 ⁶ pieces sowing, and cultured for 24 hours in 5% C0 ₂ under 37 ° C. Transfection was performed using ribofectamine (GIBC0BRL). That is, 125 zl lipofectamine, 1001 PLUS Reagent, hPPARr expression plasmid (plasmid pTBT-hPPARa obtained in Reference Example 3a) and hRXRo! Expression plasmid (plasmid obtained in Reference Example 1a). p TBT— h RXR) in 2.5 g each, repo overnight plasmid (repo overnight plasmid pGL3-4ERP P-TK neo obtained in Reference Example 2a) 5 g, RL-Tk (Pr omega) was mixed with 5 and opti-MEM (GIBCO BRL) to prepare a transfection mixture. 25 ml of transfusion mixture was added to COS-1 cells, and the cells were cultured at 37 ° C. under 5% CO ₂ for 3 hours. Then, DMEM medium (Nikken Biomedical Institute) containing 0.1% BSA (fatty acid free) (Wako Pure Chemical) was added 25 ml, further, 37 ° C, 5% C0 24 hours at ₂ under culture did.

Reference example 3

4-[((4-Chloromethyl-12-methoxyphenoxy) methyl] -2- (2-furyl) -15-methyloxazole (1.47 g), 3- (3-phenyl-2-H-pyrazo Sodium hydride (60%, oily, 0.16 g) was added to a mixture of 1- (41-yl) ethyl propionate (0.90 g) and Ν, Ν-dimethylformamide (50 mL) at room temperature. The reaction mixture was stirred at room temperature for 4 hours. Water was poured into the reaction mixture, which was extracted with ethyl acetate. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate, and concentrated, and the residue obtained was concentrated. 3-[1-(4-{[2- (2-furyl)-15 -methyl-4 -oxazolyl] methoxy}} _ 3 from the elution part of ethyl acetate-hexane (1: 2, v / v) —Methoxybenzyl) -1-3-phenyl 1 H—pyrazol-1-yl] ethyl propionate was obtained as a colorless oil (1.90 g, yield 95%).

_{'H-NMR (CDC1 3)} δ: 1.18 (3Η, t, J-7.2 Hz), 2.41 (3H, s), 2.52 (2H, t, J = 7.4 Hz), 2.95 (2H, t, J = 7.4 Hz), 3.83 (3H, s), 4.07 (2H, q, J = 7.2 Hz), 5.05 (2H, s), 5.23 (2H, s), 6.52 (1H, dd, J = 3.6, 1.8 Hz), 6.79-6.83 (2H, m), 7.95-7.02 (2H, m), 7.20-7.46 (4H, m), 7.53-7.54 (1H, m), 7.61-7.66 (2H, m).

Reference example 4

 3-[1- (4-({2- (2-furyl) -1 5-methyl-4 oxazolyl] methoxy) -1-3-methoxybenzyl) -3- phenyl 1 H-pyrazole-4 yl ] To a mixture of ethyl propionate (1.90 g), tetrahydrofuran (7 mL), and ethanol (7 mL) was added a 1N aqueous solution of sodium oxide (7 mL), and the mixture was stirred at 50 for 1 hour. 1N hydrochloric acid (7 mL) and water were added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer is washed with saturated saline, dried over anhydrous magnesium sulfate, and concentrated to give 3- [1-1 (4-{[2- (2-furyl) -5-methyl-4-oxazolyl] methoxy}. — Crystals of —3-methoxybenzyl) -1-phenyl-1-H-pyrazole-4-yl] propionic acid were obtained (1.50 g, yield 83%). Recrystallization from ethyl acetate-hexane gave colorless prisms. Melting point 125-126 ° C

Reference example 5

4-[(4-chloromethyl-2-methoxyphenoxy) methyl] -1- (2-furyl) -1-5-methyloxazole (11.48 g), 3-phenyl-2-H-pyrazole-14 A mixture of ethyl rubonate (4.95 g), anhydrous potassium carbonate (3.48 g) and Ν, Ν-dimethylformamide (100 mL) was stirred at 90 for 15 hours. The reaction mixture was poured into water and extracted with ethyl acetate. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate, and concentrated. The residue obtained was subjected to silica gel column chromatography, and eluted with ethyl acetate-hexane (1: 2, v / v). From, 1 1 (4 1 {[2- (2-furyl) -5-methyl-4 4-year-old xazolyl] methoki A crystal of (3- (3-methoxybenzyl) -3-phenyl-1H-pyrazol-4 (4) -ethyl ribonate was obtained. Recrystallization from ethyl acetate-hexane gave colorless prisms (6.47 g, yield 55D, mp 123-124).

Reference example 6

 1- (4-{[2- (2-furyl) -5-methyl-4 4-oxazolyl] methoxy} -3-3-methoxybenzyl) -1-phenyl-2 H-pyrazole-4 mono-rubonate ( To a solution of 6.28 g) in tetrahydrofuran (100 mL) was added lithium aluminum hydride (0.46 g) at 0 ° C, followed by stirring at room temperature for 2 hours. Sodium sulfate, 10-hydrate (3.93 g) was added to the reaction mixture, and the mixture was stirred at room temperature for 30 minutes. The reaction mixture was diluted with ethyl acetate, the precipitate was removed by filtration, and the filtrate was concentrated. The obtained crystals are collected by filtration, and [1- (4-{[2- (2-furyl) -15-methyl-4-4-oxazolyl] methoxy} -13-methoxybenzyl) -13-phenyl-1H-pyrazole- 4- [yl] methanol was obtained (5.61 g, 98% yield). Recrystallized from ethyl acetate-hexane. 125-126.

Reference Example 7

 [1- (4-[{2- (2-furyl) -1-5-methyl-4-one-xazolyl] methoxy] — .3-—methoxybenzyl) -3-phenyl-1H-pyrazole-4-propyl] methanol ( 3.0 g), a mixture of activated manganese dioxide (10.0 g) and tetrahydrofuran (100 ml) was stirred at room temperature for 3 days. After removing manganese dioxide by filtration, the filtrate was concentrated and the resulting crystals were collected by filtration, and 1_ [4-[[2- (2-furyl) -15-methyl-41-year-old xazolyl] methoxy 1-Methoxybenzyl] —3 1-phenyl-1H-pyrazol-l-4-phenol-aldehyde was obtained (2.62 g, 87% yield). Recrystallized from ethyl acetate-hexane. 106-107 ° C.

Reference Example 8

A mixture of thiopropionamide (3.0 g), 1,3-dichloro-2-propanone (4.70 g) and ethanol (50 mL) was heated under reflux for 1.5 hours. The reaction mixture was concentrated, and ethyl acetate was added to the residue. The mixture was washed successively with saturated aqueous sodium hydrogen carbonate and saturated brine, dried over anhydrous magnesium sulfate, and concentrated. The obtained residue was subjected to silica gel column chromatography, and the residue was purified with ethyl acetate. From the elution part of the xanthane (1: 6, v / v), 4-monochloromethyl-2-ethylthiazole was obtained as a brown oil (4.87 g, yield 90%).

_{'H-NMR (CDC1 3)} 6: 1.40 (3H, t, J = 7.2 Hz), 3.04 (2H, q, 1 = 1.2 Hz), 4.67 (2H, s), 7.16 (1H, s).

Reference Example 9

 4. A mixture of monochloromethyl-2-ethylthiazole (4.87 g), triphenylphosphine (7.89 g), and acetonitrile (10 OmL) was heated to reflux for 15 hours. After concentrating the reaction mixture, the precipitated crystals were washed with getyl ether to give [(2-ethyl-4-thiazolyl) methyl] triphenylphosphonium chloride as colorless crystals (10.02 g, 79% yield). Obtained. Recrystallized from Acetonitrile Luetjer. Mp 222-223. Example 1

3- [1- (4-{[2- (2-furyl) -5-methyl-4 oxazolyl] methoxy} _- 3-methoxybenzyl) -1-3-phenyl-1H-pyrazol-4-yl] propionic acid To a solution of (0.60 g) in tetrahydrofuran (80 mL), 4-methyl morpholine (0.16 g) and isobutyl carbonate (0.23 g) were sequentially added at 0. The reaction mixture was stirred at room temperature for 1 hour, insolubles were removed by filtration, and the filtrate was added dropwise to a mixture of hydrazine monohydrate (0.30 g) and tetrahydrofuran (20 mL) at 0 ° C. The reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was diluted with ethyl acetate, washed successively with a saturated aqueous solution of ammonium chloride and brine, dried over anhydrous magnesium sulfate, and concentrated. A mixture of the obtained residue, trimethyl orthobutyrate (0.54 g), methanesulfonic acid (0.02 g) and 1,4-dioxane (50 mL) was stirred with litre for 1 hour. The reaction mixture was concentrated, ethyl acetate was added to the residue, and the mixture was washed successively with saturated aqueous sodium hydrogen carbonate and saturated brine, dried over anhydrous magnesium sulfate, and concentrated. The obtained residue was subjected to silica gel column chromatography, and 2- (2-) [1- (4-([{2- (2-furyl) -one) was obtained from the eluate of ethyl hexane acetate (1: 4, vZv). 5-Methyl-4xoxazolyl] methoxy} -1-methoxybenzyl-3-1-phenyl-1H-birazol-4-yl] ethyl} -1-propyl Crystals of 1,3,4-oxadiazole were obtained (0.49 g, yield 70%). Recrystallization from ethyl acetate-hexane gave colorless prisms. Melting point 123-124

Example 2

1- (4-{[2- (2-furyl) -5-methyl-4-oxazolyl] methoxy} -1-methoxybenzyl) -1-3-phenyl-1H-pyrazole-4 lipoaldehyde (0.70 g) Sodium hydride (60%, oily, 0.07 g) was added to a mixture of methylenediphosphonate tetraethyl (0.49 g) and Ν, Ν-dimethylformamide (30 mL) at room temperature. The reaction mixture was stirred at room temperature for 2 days. Water was poured into the reaction mixture, which was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous magnesium sulfate, and concentrated. The obtained residue was subjected to silica gel column chromatography, and from the eluted portion of ethyl acetate-hexane (5: 1, v / v), (E) -1- (1-1 (4-furyl) 1-1 5-Methyl-14-year-old xazolyl] methoxy} -3-methoxybenzyl) -1-phenyl-1-H-pyrazole-41-yl] ethenylphosphonate getyl was obtained as a colorless oil (0.52 g, yield). 57%). _{Ή-NMR (CDC1 3) δ} : 1.31 (6Η, t, J = 7.0 Hz), 2.42 (3H, s), 3.85 (3H, s), 4.05 (2H, q, J = 7.0 Hz), 4.09 (2H , q, J-7.0 Hz), 5.06 (2H, s), 5.26 (2H, s), 5.86 (1H, dd, J = 18.6, 17.6 Hz), 6.52 (1H, dd, J = 3.4, 1.8Hz) , 6.84-7.07 (4H, m), 7.32-7.59 (8H, m).

Example 3

3-[[1-({6-[(5-Methyl-2-phenyl-4-oxazolyl) methoxy] -3-1-pyridyl} methyl) -1-3-phenyl-1H-pyrazol-4-yl] propionic acid ( To a solution of 0.40 g) in tetrahydrofuran (50 mL) was added 4-monomethylmorpholine (0.11 g) and isobutyl carbonate (0.15 g) sequentially at 0 ° C. The reaction mixture was stirred at 0 ° C. for 1 hour, insolubles were removed by filtration, and the filtrate was added dropwise to a mixture of hydrazine monohydrate (0.21 g) and tetrahydrofuran (30 mL) at 0. The reaction mixture was stirred at 0 for 1 hour. The reaction mixture was diluted with ethyl acetate, washed successively with a saturated aqueous solution of ammonium chloride and saturated saline, dried over anhydrous magnesium sulfate, and concentrated. The resulting residue, a mixture of trimethyl orthobutyrate (0.36 g), methanesulfonic acid (0.015 g) and tetrahydrofuran (50 mL) was treated for 1.5 hours. Heated to reflux. Ethyl acetate was added to the reaction mixture, and the mixture was washed successively with saturated aqueous sodium hydrogen carbonate and saturated brine, dried over anhydrous magnesium sulfate, and concentrated. The obtained residue was subjected to silica gel column chromatography, and from the eluate of ethyl acetate-methanol (50: 1, vZv), 2-[(5-methyl-2-phenyl-2-oxazolyl) methoxy] -5- ({3-Fueneru 4- [2- (5-Propyl-1,3,4-oxaziazol-1-2-yl) ethyl] -1 H-pyrazol-1-yl} methyl) Pyridine as a colorless oil (0.31 g, yield 69%).

_{NMR (CDC1 3) δ: 0.97} (3H, t, J = 7.4 Hz), 1.63-1.84 (2H, m), 2.48 (3H, s), 2.73 (2H, t, J = 7.4 Hz), 2.97-3.17 (4H, m), 5.22 (2H, s), 5.30 (2H, s), 6.81 (1H, d, J = 8.0 Hz), 7.29-7.62 (10H, m), 7.99-8.04 (2H, m), 8.13 (1H, d, J = 1.8 ^ z). '

Example 4

1- (4 — {[2- (2-furyl) -1-methyl-4-4-oxazolyl] methoxy} —3-methoxybenzyl) —3-phenyl-2-H-pyrazole-4-l-propaldehyde (1.16 g), A mixture of [(2-ethyl-4'-thiazolyl) methyl] triphenylphosphonium chloride (1.61 g), anhydrous potassium carbonate (0.53 g) and Ν, Ν-dimethylformamide (30 mL) was added at room temperature for 15 hours. Stirred. Water was poured into the reaction mixture, which was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated. The obtained residue was subjected to silica gel column chromatography, and eluted with ethyl acetate-hexane (2: 3 to 3: 2, v / v) to give {{4-({4-[(Z) 2- (2-Technyl 4-thiazolyl) ethenyl] -1-3-phenyl-1H-pyrazole-1-yl} methyl) -1-2-methoxyphenoxy] methyl} -1-2- (2-furyl) -5-methyloxazozo One liter was obtained as a colorless oil (0.08 g, 6% yield). P 丽 R (CDC1 ₃ ) 5: 1.33 (3H, t, J = 7.6 Hz), 2.41 (3H, s), 2.92 (2H, q, J = 7.6 Hz), 3.83 (3H, s), 5.05 ( 2H, m), 5.27 (2H, s), 6.37 (1H, d, J = 12.4 Hz), 6.45 (1H, d, J = 12.4Hz), 6.51-6.54 (1H, m), 6.80-6.88 (2H , M), 6.95-7.03 (3H, m), 7.34-7.46 (4H, m), 7.53-7.54 (1H, m), 7.66-7.69 (2H, m), 8.25 (1H, s). In addition, from the elution part obtained subsequently, 4-{[4-— ({4- [(E) -2- (2-ethyl- 4-thiazolyl) ethenyl) ethenyl] -1-3-phenyl-2 H-pyrazol-1-yl Methyl} -2-methoxyphenoxy] methyl} -12- (2-furyl) -15-methyloxazole was obtained as a colorless oil (1.19 g, yield 82%). _{'H-NMR (CDC1 3)} 5: 1.38 (3H, t, J = 7.4 Hz), 2.41 (3H, s), 3.01 (2H, q, J = 7.4 Hz), 3.84 (3H, s), 5.06 ( 2H, s), 5.28 (2H, s), 6.50-6.54 (1H, m), 6.74 (1H, d, J = 15.6 Hz), 6.85-7.06 (5H, m), 7.26-7.54 (6H, m) , 7.65-7.69 (2H, m).

Example 5

 1- [4- (5-Methyl-2-phenyl-4-oxazolylmethoxy) benzyl] 1-3- (2-Chenyl) 1-1H-pyrazole-4-carbaldehyde (1.0 g), [( A mixture of 2-ethyl-4'-thiazolyl) methyl] triphenylphosphonium chloride (1.40 g), anhydrous potassium carbonate (0.46 g) and N, N-dimethylformamide (3 OmL) was stirred at room temperature for 15 hours. Water was poured into the reaction mixture, which was extracted with ethyl acetate. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate, and concentrated. The obtained residue was subjected to silica gel column chromatography, and eluted with ethyl acetate-hexane (2: 3 to 3: 2, v / v) to give 4-{[4-1-1 ({4--1 [(E) -2- (2-Ethyl-4-1thiazolyl) ethenyl]-3- (2-Chenyl) -1H-pyrazole-1-yl} methyl) phenoxy] methyl} -1-methyl-2-phenyl-2-oxazole As obtained. (0.95 g, 77% yield).

_{'H-NMR (CDC1 3)} δ: 1.40 (3Η, t, J = 7.5 Hz), 2.44 (3H, s), 3.03 (2H, q, J = 7.5 Hz), 5.00 (2H, s), 5.26 ( 2H, s), 6.75 (1H, d, J = 15.9 Hz), 6.90 (1H, s), 7.00-7.12 (3H, m), 7.25-7.6 (9H, m), 7.99-8.02 (2H, m).

Example 6

1 _ [4- (5-Methyl-2-phenyl-2-oxazolylmethoxy) benzyl] -3- (2-Chenyl) 1-1H-pyrazole-4-carpoaldehyde (0.46 g), A mixture of tetraethyl methylenediphosphonate (0.32 g) and Ν, Ν-dimethylformamide (2 OmL) was added to sodium hydride (60%, Oily, 0.05 g) was added at room temperature. The reaction mixture was stirred at room temperature for 2 hours. Water was poured into the reaction mixture, which was extracted with ethyl acetate. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate, and concentrated. The obtained residue was subjected to silica gel column chromatography, and eluted with ethyl acetate-hexane (4: 1 force, 9: 1, v / v) to give (Z)-2-(1-{ 4-[(5-Methyl-2-phenyl-4-oxazolyl) methoxy] benzyl} -3- (2-Chenyl) -1H-pyrazol-l-41-yl) Jetyl ethenylphosphonate was obtained as a colorless oil ( 0.05 g, 8% yield).

_{Ή-NMR (CDC1 3) δ} :. 1.21 (6Η, t, J = 7.2 Hz), 2.43 (3H, s), 3.90-4.05 (4H, m), 4.97 (2H, s), 5.26 (2H, s ), 5.57 (1H, dd, J = 16.8, 14.4 Hz), 6.96-7.45

(11H, m), 7.98-8.03 (2H, m), 8.49 (1H, s).

 From the eluted part obtained subsequently, (E) -2- (1-1 {4-[(5-methyl-12-phenyl-2-oxazolyl) methoxy] benzyl} -3- (2-phenyl) 1-1 Getyl H-pyrazole-4-yl) ethenylphosphonate was obtained as a colorless oil (0.36 g, 61% yield).

_{Ή-NMR (CDC1 3) δ} : 1.33 (6Η, t, J = 7.0 Hz), 2.45 (3H, s), 4.01-4.16 (4H, m), 5.00 (2H, s), 5.25 (2H, s) , 5.89 (1H, dd, J = 18.6, 17.4 Hz), 7.01-7.12

(3H, m), 7.25-7.65 (9H, m), 7.99-8.04 (2H, m) ₀

Example Ί

1- [4- (5-Methyl-2-phenyl-4-oxazolylmethoxy) benzyl] —4-phenylpyrroyl-3-hydroxylaldehyde (6 Omg) and tetraethyl methylenebisphosphonate (46 mg) It was dissolved in N, N-dimethylformamide (6 mL). Sodium hydride (60%, oily, 6.5 mg) was added to the resulting solution at room temperature, and the mixture was stirred for 16 hours. The reaction mixture was poured into water, neutralized with 2N hydrochloric acid, and extracted with ethyl acetate. The ethyl acetate layer was washed with water, dried over anhydrous magnesium sulfate, and concentrated. The residue was subjected to silica gel column chromatography. From the eluted portion of acetone / hexane (1: 2, v / v), (E) 1-2— {1— [4 -— (5-methyl-2-phenyl) _4 1-oxazolyl methoxy) pendyl] 1-phenylphenylpyrrole-3-yl} ethenylphosphonic acid di Ethyl (56 mg, yield 72%) was obtained as a colorless oil.

Ή-丽 R (CDC1 ₃ ) δ: 1.30 (6H, t, J = 7 Hz), 2.44 (3H, s), 3.9-4.15 (4H, m), 4.99 (4H, s), 5.77 (1H, dd , J = 20, 17.5 Hz), 6.69 (1H, d, J = 2 Hz), 6.95-7.55 (14H, m), 7.95-8.1 (2H, m).

Example 8

 1- [4- (5-Methyl-2-phenyl-4-oxazolylmethoxy) benzyl] 1-4-phenylpyrroyl-1-carbaldehyde (l O Omg), [(2-ethyl-4-thiazolyl) A mixture of [methyl] triphenylphosphonium chloride (140 mg), anhydrous potassium carbonate (47 mg) and N, N-dimethylformamide (10 mL) was stirred at 100 ° C for 24 hours. The reaction mixture was poured into water, neutralized with 2N hydrochloric acid, and extracted with ethyl acetate. The ethyl acetate layer was washed with water, dried over anhydrous magnesium sulfate, and concentrated. The residue was subjected to silica gel column chromatography. From the eluted portion of ethyl acetate-hexane (1: 4, v / v), 4-{[4-1 ({3-[(E) -2- (2-ethyl-4- Thiazolyl) ethenyl] —4-phenylpyrroyl-1-yl} methyl) phenoxy] methyl} -15-methyl-2-phenyloxyxazole (3 Omg, 24% yield) was obtained as a colorless oil. .

 'H-NMR (CDC1 J δ: 1.38 (3H, t, J = 7.5 Hz), 2.44 (3H, s), 3.01 (2H, q, J = 7.5 Hz), 4.99 (2H, s), 5.01 (2H , s), 6.71 (1H, d, J = 2 Hz), 6.73 (1H, d, J = 16 Hz), 6.8K1H, s), 6.95 (1H, d, J = 2 Hz), 7.01 (2H, d, J = 9 Hz), 7.19 (2H, d, J = 9 Hz), 7.2-7.55 (9H, m), 7.95-8.1 (2H, m). Formulation Example 1 (Manufacture of capsules)

 1) 30 mg of the compound of Example 1 2) 10 mg of finely divided cellulose

3) Lactose 19 mg

 4) Magnesium stearate 1 mg

 60 mg in total

1), 2), 3) and 4) are mixed and filled into a gelatin capsule. Formulation Example 2 (tablet production)

 1) 30 g of the compound of Example 1

2) Lactose 50 g

3) Corn starch 15 g 4) Carboxymethylcellulose calcium 44 g 5) Magnesium stearate 1

 1000 tablets Total 140 g Knead the total amount of 1), 2) and 3) and 30 g of 4) with water, dry under vacuum, and size. 14 g of 4) and 1 g of 5) are mixed with the sized powder and tableted with a tableting machine. In this way, 1000 tablets each containing 30 mg of the compound of Example 1 are obtained. Industrial applicability

 The compound of the present invention is excellent in blood glucose lowering action, blood lipid lowering action, blood insulin lowering action, insulin resistance improving action, insulin sensitivity enhancing action and retinoid-related receptor function regulating activity, for example, diabetes (eg, type 1) Prevention and treatment of diabetes mellitus, type 2 diabetes, gestational diabetes mellitus, etc .; prevention of hyperlipidemia (eg, hypertriglyceridemia, hypercholesterolemia, hypo-HDLemia, postprandial hyperlipidemia, etc.) Insulin sensitizer; Insulin sensitivity enhancer; Prevention of impaired glucose tolerance [IGT (Impaired Glucose Tolerance)]. It can be used as a therapeutic agent and an inhibitor of the transition from impaired glucose tolerance to diabetes.

Claims

The scope of the claims 1. General formula

[Wherein, R ¹ is an optionally substituted hydrocarbon group or an optionally substituted X and Y are the same or different bond, an oxygen atom, a sulfur atom, One CO-, - CS-, One SO- one S_〇 _{^{2 -, -CR 3 (OR 4}} ) one one NR ⁵ - one CO NR ⁶ -or --NR ⁶ CO_ (R ³ is a hydrogen atom or an optionally substituted hydrocarbon group, R ⁴ is a hydrogen atom or a hydroxyl-protecting group, R ⁵ is a hydrogen atom, R ⁶ represents a hydrogen atom or an optionally substituted hydrocarbon group); Q represents a divalent hydrocarbon residue having 1 to 20 carbon atoms; Ring A is an aromatic ring which may further have 1 to 3 substituents; n is an integer of 1 to 8; Ring B is a nitrogen-containing 5-membered heterocyclic ring which may further have 1 to 3 substituents;  W represents a divalent hydrocarbon residue having 1 to 20 carbon atoms; V is a bond, an oxygen atom, a sulfur atom, - SO-, one S0 ₂ -, one NR ⁷ -, or - NR ⁷ CO- the (R ⁷ is a hydrogen atom or an optionally substituted hydrocarbon group) ; R ² is one PO (OR ⁸ ) (OR ⁹ ) (R ⁸ and R ⁹ are the same or different and each represent a hydrogen atom or an optionally substituted hydrocarbon group, and R ⁸ and R ⁹ are (Which may form a ring which may be substituted), COR ^1Q (R ^1Q represents a hydrogen atom or a hydrocarbon group which may be substituted), a hydrocarbon group which may be substituted or substituted A heterocyclic group which may be substituted. However, ring B is represented by the formula: — Wa— (C = 0) -R ^a (Wa is a bond or a divalent hydrocarbon residue having 1 to 20 carbon atoms, and R ^a is 1 ^Rb (R ^b is hydrogen Atom or substituted Or NR ^d (R ^e and R ^d are the same or different and are a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, or substituted And R ^e and R ^d may be bonded to form a ring). When V is a bond, R ² is — (C = 0) —R ^e (R ^e is _0R ^f (R ^f is a hydrogen atom or an optionally substituted hydrocarbon group) or — NR ^g R ^h (R ^g and R ^h are the same or different and each represent a hydrogen atom, a hydrocarbon group which may be substituted, a heterocyclic group which may be substituted, or an acyl group which may be substituted; R ^g and R ^h may be combined with each other to form a ring). However, R ^g and R ^h are not a hydrocarbon group substituted with the substituent represented by ] The compound represented by these, or its salt. 2. X is a bond, oxygen atom, sulfur atom, one CO-, one CS-, one CR ³ (OR ⁴ ) one or one NR ⁵ — (R ³ is a hydrogen atom or a hydrocarbon group which may be substituted. R ⁴ represents a protecting group for a hydrogen atom or a hydroxyl group, and R ⁵ represents a protecting group for a hydrogen atom, an optionally substituted hydrocarbon group or an amino group); Y is a bond, an oxygen atom, a sulfur atom, -SO-, one S0 ₂ -, one NR ⁶ -, one C ONR ⁶ - or - NR ⁶ CO- (R ⁶ is not good be hydrogen atom or a substituent The compound according to claim 1, which represents a hydrocarbon group). 3. The compound according to claim 1, wherein R ¹ is an optionally substituted heterocyclic group.  4. The compound according to claim 1, wherein X is a bond. 5. The compound according to claim 1, wherein Y is an oxygen atom.  6. The compound according to claim 1, wherein the substituent which ring B may further have is a hydrocarbon group.  7. The compound according to claim 6, wherein the hydrocarbon group is an alkyl group having 1 to 10 carbon atoms, an aralkyl group having 7 to 13 carbon atoms, or an aryl group having 6 to 14 carbon atoms.  8. The compound according to claim 1, wherein V is a bond. 9. R ^{2 is} —PO (OR ⁸ ) (OR ⁹ ) (R ⁸ and R ⁹ are the same or different and represent a hydrogen atom or an optionally substituted hydrocarbon group, and R ⁸ and R ⁹ are a bond and may form a ring which may be optionally substituted), one COR ¹⁰ 2. The compound according to claim 1, wherein R ^{1 Q} represents a hydrogen atom or an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group.  10. A prodrug of the compound of claim 1 or a salt thereof.  11. A pharmaceutical composition comprising the compound according to claim 1, a salt thereof, or a prodrug thereof.  12. The pharmaceutical composition according to claim 11, which is an agent for preventing and treating diabetes.  13. The pharmaceutical composition according to claim 11, which is an agent for preventing or treating hyperlipidemia.  14. The pharmaceutical composition according to claim 11, which is an agent for preventing or treating glucose intolerance. 15. The pharmaceutical composition according to claim 11, which is an agent for preventing and treating obesity. 16. A retinoid-related receptor function modulator comprising the compound according to claim 1 or a salt thereof or a prodrug thereof.  17. The agent according to claim 16, which is a peroxisome proliferator-activated receptor ligand.  18. The agent according to claim 16, which is a retinoid X receptor ligand. 19. An insulin resistance improving agent comprising the compound according to claim 1 or a salt thereof or a prodrug thereof.  20. A method for treating diabetes in a mammal, comprising administering the compound according to claim 1 or a salt thereof or a prodrug thereof to a mammal. 21. A method for treating hyperlipidemia in a mammal, which comprises administering the compound according to claim 1 or a salt thereof or a prodrug thereof to a mammal.  22. A method for treating obesity in a mammal, comprising administering the compound according to claim 1 or a salt thereof or a prodrug thereof to a mammal. 23. Use of the compound according to claim 1 or a salt thereof or a prodrug thereof for producing a prophylactic / therapeutic agent for diabetes.  2 4. Use of the compound according to claim 1 or a salt thereof or a prodrug thereof for producing an agent for preventing or treating hyperlipidemia.  25. Use of the compound according to claim 1 or a salt thereof or a prodrug thereof for producing an agent for preventing or treating obesity.